Succinic Semialdehyde Dehydrogenase Deficiency

Mendelian MONDO:0010083 Pathograph 33 gamma-amino butyric acid metabolism disorder Inborn error of metabolism

Succinic semialdehyde dehydrogenase deficiency is an autosomal recessive neurometabolic disorder of GABA metabolism caused by biallelic ALDH5A1 pathogenic variants. The clinical spectrum ranges from mild to severe and commonly includes intellectual disability, developmental delay, hypotonia, ataxia, epilepsy, and behavioral dysregulation.

Ask OpenScientist

Ask a research question about Succinic Semialdehyde Dehydrogenase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
6
Pathophys.
21
Phenotypes
33
Pathograph
1
Genes
2
Treatments
1
Trials
2
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0010083 succinic semialdehyde dehydrogenase deficiency
skos:exactMatch MONDO
MONDO exact match for Orphanet ORPHA:22 and OMIM:271980.
👪

Inheritance

1
Autosomal recessive HP:0000007
Autosomal recessive inheritance
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance for SSADH deficiency.
⚙

Pathophysiology

6
ALDH5A1 Pathogenic Variants
Biallelic ALDH5A1 pathogenic variants are the initiating molecular cause of SSADH deficiency.
ALDH5A1 link
Downstream
Succinate-Semialdehyde Dehydrogenase Catalytic Block ALDH5A1 encodes succinic semialdehyde dehydrogenase, so pathogenic variants reduce the enzyme's catalytic conversion of succinic semialdehyde to succinate.
Show evidence (2 references)
ORPHA:22 SUPPORT Other
"ALDH5A1 | aldehyde dehydrogenase 5 family member A1 | hgnc:408 | Disease-causing germline mutation(s) in"
Orphanet identifies ALDH5A1 germline variants as disease causing in SSADH deficiency.
PMID:39011401 SUPPORT Human Clinical
"The disorder is due to bi-allelic pathogenic variants in ALDH5A1 and is usually characterized by moderate-to-severe developmental delays, hypotonia, intellectual disability, ataxia, seizures, hyperkinetic behavior, aggression, psychiatric disorders, and sleep disturbances."
A diagnostic cohort study directly links SSADH deficiency to biallelic ALDH5A1 pathogenic variants.
Succinate-Semialdehyde Dehydrogenase Catalytic Block
Loss of SSADH activity blocks the mitochondrial oxidation of succinic semialdehyde to succinate in the GABA catabolic pathway.
GABA metabolic process link ⚠ ABNORMAL GABA catabolic process link ↓ DECREASED
succinate-semialdehyde dehydrogenase (NAD+) activity link ↓ DECREASED
mitochondrion link
Downstream
GABA and 4-Hydroxybutyrate Accumulation When SSADH cannot oxidize succinic semialdehyde to succinate, GABA-pathway intermediates are diverted toward GHB and related metabolites.
Show evidence (2 references)
PMID:32967698 SUPPORT Human Clinical
"The product of glutamate decarboxylation, GABA is catabolized to succinic acid in a two-enzyme sequence, including generation of succinic semialdehyde (SSA) catalyzed by GABA-aminotransferase and the further oxidation of SSA to succinic acid catalyzed by SSADH [10]."
Human biomarker-study background defines the blocked SSADH-catalyzed oxidation step.
PMID:27896081 SUPPORT Human Clinical
"Succinic semialdehyde dehydrogenase (SSADH; EC 1.2.1.24) deficiency is a rare disorder (OMIM 271980) of γ-aminobutyric acid (GABA) degradation caused by mutations in ALDH5A1[1], [2]."
Human case report supports ALDH5A1-driven SSADH deficiency as a GABA-degradation disorder.
GABA and 4-Hydroxybutyrate Accumulation
Impaired GABA catabolism produces elevated GABA and 4-hydroxybutyrate/GHB in patient body fluids, with GHB and related metabolites forming a diagnostic metabolic signature.
GABA catabolic process link ↓ DECREASED
Downstream
GABAergic Network Dysfunction Accumulated GABA-pathway metabolites perturb neuronal signaling in a disorder centered on GABAergic neurotransmission.
Basal Ganglia Vulnerability GABA/GHB accumulation affects basal ganglia-rich neural circuits, consistent with globus pallidus neuropathology and MRI abnormalities.
Abnormality of metabolism/homeostasis Elevated GABA, GHB, and related metabolites constitute the core metabolic homeostasis abnormality in SSADH deficiency.
Elevated 4-hydroxybutyric acid SSADH deficiency elevates GHB/4-hydroxybutyric acid as a core diagnostic metabolite.
Elevated gamma-aminobutyric acid Impaired GABA catabolism elevates GABA in physiological fluids.
Elevated 4,5-dihydroxyhexanoic acid Untargeted and targeted metabolomics show 4,5-DHHA elevation alongside GHB in SSADH deficiency.
Oxidative and Mitochondrial Stress Metabolite accumulation is associated with redox imbalance and mitochondrial dysfunction in patient and model evidence.
Show evidence (2 references)
PMID:37455357 SUPPORT Human Clinical
"Targeted analysis of NGMS data from cerebrospinal fluid (CSF) showed a moderate increase of aspartic acid, glutaric acid, glycolic acid, 4-guanidinobutanoic acid, and 2-hydroxyglutaric acid, and prominent elevations of GHB and 4,5-dihydroxyhexanoic acid (4,5-DHHA) in SSADHD samples."
Patient metabolomics demonstrates prominent GHB and 4,5-DHHA elevations.
PMID:32967698 SUPPORT Human Clinical
"The metabolic signature includes elevated GHB and GABA in physiological fluids, among other metabolites [11]."
Human biomarker study summarizes the elevated GHB and GABA metabolic signature.
Basal Ganglia Vulnerability
GABA-rich basal ganglia structures, especially the globus pallidus, are a recurrent neuroanatomical focus in SSADH deficiency, linking the metabolic neurotransmitter defect to movement features and characteristic MRI signal abnormalities.
synaptic transmission, GABAergic link ⚠ ABNORMAL
basal ganglion link globus pallidus link
Downstream
Focal T2 hyperintense basal ganglia lesion Basal ganglia vulnerability is reflected by recurrent globus-pallidus and basal-ganglia T2 hyperintensity on MRI.
Dystonia Basal ganglia circuit involvement can contribute to dystonia within the SSADH movement-disorder spectrum.
Chorea Basal ganglia circuit involvement can contribute to chorea within the SSADH movement-disorder spectrum.
Exertional dyskinesia Basal ganglia circuit involvement can contribute to exertional dyskinesia within the SSADH movement-disorder spectrum.
Show evidence (1 reference)
PMID:31117962 SUPPORT Human Clinical
"Cerebral MRI showed symmetrical hyperintense signal of bilateral globus pallidus and basal ganglia in patient 1"
Human case-series evidence documents globus-pallidus and basal-ganglia involvement on MRI.
GABAergic Network Dysfunction
Patient-derived GABAergic neuronal models and longitudinal human data support altered inhibitory/excitatory signaling as a contributor to epilepsy, developmental delay, movement features, sleep disturbance, and psychiatric manifestations.
GABAergic neuron link
synaptic transmission, GABAergic link ⚠ ABNORMAL synaptic transmission, glutamatergic link ↑ INCREASED
Downstream
Intellectual disability GABAergic network dysfunction contributes to impaired neurocognitive development.
Global developmental delay Altered early-life inhibitory signaling contributes to developmental delay.
Hypotonia Neurodevelopmental network dysfunction contributes to low muscle tone.
Ataxia Central nervous system dysfunction contributes to impaired coordination.
Bilateral tonic-clonic seizure Altered neuronal excitability contributes to epilepsy and convulsive seizures.
Status epilepticus Severe seizure susceptibility can progress to prolonged seizures.
Generalized myoclonic seizure Altered neuronal excitability contributes to generalized myoclonic seizures.
Sudden unexpected death in epilepsy The epilepsy phenotype carries a recognized SUDEP risk in SSADH deficiency.
Expressive language delay Early-life neurotransmitter network dysfunction contributes to prominent language-development delay.
Sleep disturbance GABAergic network dysfunction contributes to sleep dysregulation.
Autism Altered inhibitory and excitatory signaling contributes to autistic features in the core neurodevelopmental phenotype.
Atypical behavior Neurodevelopmental network dysfunction contributes to behavioral dysregulation.
Anxiety GABAergic network dysfunction contributes to anxiety in the neuropsychiatric phenotype.
Obsessive-compulsive trait Altered inhibitory signaling contributes to obsessive-compulsive behaviors in the neuropsychiatric phenotype.
Attention deficit hyperactivity disorder GABAergic network dysfunction contributes to short attention span and distractibility in the behavioral phenotype.
Aggressive behavior Neuropsychiatric dysregulation can include aggression and related behavioral symptoms.
Show evidence (3 references)
PMID:38658850 SUPPORT Human Clinical
"Autism, epilepsy, movement disorders, sleep disturbances, and various psychiatric behaviors constituted the core of the disorder's clinical phenotype."
Natural-history cohort evidence defines the major neurologic and neuropsychiatric phenotype cluster.
PMID:38658850 SUPPORT In Vitro
"iPSCs, which were differentiated into GABAergic neurons, represent the first in vitro neuronal model of SSADHD and express the neuronal marker microtubule-associated protein 2 (MAP2), as well as GABA."
Patient-derived in vitro GABAergic neurons support a neuronal model for the signaling mechanism.
PMID:38658850 SUPPORT In Vitro
"GABA-metabolism in induced GABAergic neurons could be reversed using CRISPR correction of the pathogenic variants or mRNA transfection and SSADHD iPSCs were associated with excessive glutamatergic activity and related synaptic excitation."
Patient-derived neuronal models support increased glutamatergic synaptic excitation downstream of the SSADH metabolic defect.
Oxidative and Mitochondrial Stress
SSADH deficiency can include redox imbalance and mitochondrial dysfunction, shown in a human patient by persistently low glutathione and abnormal urinary dicarboxylic acids and supported by model evidence.
reactive oxygen species metabolic process link ⚠ ABNORMAL
Show evidence (1 reference)
PMID:27896081 SUPPORT Human Clinical
"The GSH level in our patient was 585 μM at age 5 months, 702 μM at age 9 months, and 698 μM at age 10 months (controls: 900 μM ± 140, n = 59)."
Direct patient measurements document low glutathione as a redox-stress marker.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Succinic Semialdehyde Dehydrogenase Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

21
Musculoskeletal 1
Hypotonia VERY_FREQUENT Hypotonia (HP:0001252)
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"HP:0001252 | Hypotonia | Very frequent (99-80%)"
Orphanet lists hypotonia as a very frequent phenotype.
Nervous System 14
Intellectual disability VERY_FREQUENT Intellectual disability (HP:0001249)
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"HP:0001249 | Intellectual disability | Very frequent (99-80%)"
Orphanet lists intellectual disability as a very frequent phenotype.
Ataxia VERY_FREQUENT Ataxia (HP:0001251)
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"HP:0001251 | Ataxia | Very frequent (99-80%)"
Orphanet lists ataxia as a very frequent phenotype.
Global developmental delay VERY_FREQUENT Global developmental delay (HP:0001263)
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"HP:0001263 | Global developmental delay | Very frequent (99-80%)"
Orphanet lists global developmental delay as a very frequent phenotype.
Atypical behavior FREQUENT Atypical behavior (HP:0000708)
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"HP:0000708 | Atypical behavior | Frequent (79-30%)"
Orphanet lists atypical behavior as a frequent phenotype.
Bilateral tonic-clonic seizure FREQUENT Bilateral tonic-clonic seizure (HP:0002069)
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"HP:0002069 | Bilateral tonic-clonic seizure | Frequent (79-30%)"
Orphanet lists bilateral tonic-clonic seizure as a frequent phenotype.
Generalized myoclonic seizure FREQUENT Generalized myoclonic seizure (HP:0002123)
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"HP:0002123 | Generalized myoclonic seizure | Frequent (79-30%)"
Orphanet lists generalized myoclonic seizure as a frequent phenotype.
Sleep disturbance Sleep disturbance (HP:0002360)
Show evidence (1 reference)
PMID:38658850 SUPPORT Human Clinical
"Autism, epilepsy, movement disorders, sleep disturbances, and various psychiatric behaviors constituted the core of the disorder's clinical phenotype."
The natural-history cohort identifies sleep disturbance as part of the core phenotype.
Autism Autism (HP:0000717)
Show evidence (1 reference)
PMID:38658850 SUPPORT Human Clinical
"Autism, epilepsy, movement disorders, sleep disturbances, and various psychiatric behaviors constituted the core of the disorder's clinical phenotype."
The natural-history cohort identifies autism as part of the core phenotype.
Dystonia Dystonia (HP:0001332)
Show evidence (2 references)
PMID:38499966 SUPPORT Human Clinical
"After ataxia, dystonia (19%), chorea (11%) and hypokinesia (15%) were the most frequent movement disorders."
Registry follow-up data identify dystonia as a recurrent movement phenotype.
PMID:20301374 SUPPORT Other
"movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
GeneReviews lists dystonia among common movement-disorder manifestations.
Chorea Chorea (HP:0002072)
Show evidence (1 reference)
PMID:38499966 SUPPORT Human Clinical
"After ataxia, dystonia (19%), chorea (11%) and hypokinesia (15%) were the most frequent movement disorders."
Registry follow-up data identify chorea as a recurrent movement phenotype.
Exertional dyskinesia Dyskinesia (HP:0100660)
Show evidence (1 reference)
PMID:20301374 SUPPORT Other
"movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
GeneReviews lists exertional dyskinesia among common movement-disorder manifestations.
Anxiety Anxiety (HP:0000739)
Show evidence (1 reference)
PMID:20301374 SUPPORT Other
"movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
GeneReviews lists anxiety among common neuropsychiatric features.
Attention deficit hyperactivity disorder FREQUENT Attention deficit hyperactivity disorder (HP:0007018)
Show evidence (2 references)
PMID:38499966 SUPPORT Human Clinical
"Short attention span (78.6%) and distractibility (71.4%) were the most frequently behavior traits mentioned by parents"
Registry follow-up data support frequent attention problems, represented with the closest HPO attention-deficit term.
PMID:20301374 SUPPORT Other
"movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
GeneReviews lists attention problems among common neuropsychiatric features.
Aggressive behavior Aggressive behavior (HP:0000718)
Show evidence (1 reference)
PMID:39011401 SUPPORT Human Clinical
"The disorder is due to bi-allelic pathogenic variants in ALDH5A1 and is usually characterized by moderate-to-severe developmental delays, hypotonia, intellectual disability, ataxia, seizures, hyperkinetic behavior, aggression, psychiatric disorders, and sleep disturbances."
Diagnostic cohort summary includes aggression in the typical SSADH phenotype.
Constitutional 1
Sudden unexpected death in epilepsy Sudden unexpected death in epilepsy (HP:0033258)
Show evidence (1 reference)
PMID:35269750 SUPPORT Other
"Paradoxically, over half of patients with SSADHD also develop epilepsy and face a significant risk of sudden unexpected death in epilepsy (SUDEP)."
Mechanism review identifies SUDEP as a clinically significant epilepsy-related complication.
Other 5
Abnormality of metabolism/homeostasis VERY_FREQUENT Abnormality of metabolism/homeostasis (HP:0001939)
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"HP:0001939 | Abnormality of metabolism/homeostasis | Very frequent (99-80%)"
Orphanet lists abnormal metabolism or homeostasis as a very frequent phenotype.
Status epilepticus FREQUENT Status epilepticus (HP:0002133)
Show evidence (1 reference)
ORPHA:22 SUPPORT Other
"HP:0002133 | Status epilepticus | Frequent (79-30%)"
Orphanet lists status epilepticus as a frequent phenotype.
Focal T2 hyperintense basal ganglia lesion Focal T2 hyperintense basal ganglia lesion (HP:0007183)
Show evidence (1 reference)
PMID:31117962 SUPPORT Human Clinical
"Cerebral MRI showed symmetrical hyperintense signal of bilateral globus pallidus and basal ganglia in patient 1"
Human case series documents basal-ganglia/globus-pallidus MRI hyperintensity in SSADH deficiency.
Expressive language delay Expressive language delay (HP:0002474)
Show evidence (2 references)
ORPHA:22 SUPPORT Other
"A rare neurometabolic disorder of gamma-aminobutyric acid (GABA) metabolism with a nonspecific clinical presentation (ranging from mild to severe) with the most frequent symptoms being cognitive impairment with prominent deficit in expressive language, hypotonia, ataxia, epilepsy, and behavioral..."
Orphanet's definition identifies prominent expressive-language deficit as a frequent clinical feature.
PMID:38658850 SUPPORT Human Clinical
"Language developmental delays were more prominent than motor."
The 62-subject natural-history cohort supports language delay as a prominent phenotype.
Obsessive-compulsive trait Obsessive-compulsive trait (HP:0008770)
Show evidence (1 reference)
PMID:20301374 SUPPORT Other
"movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
GeneReviews lists obsessive-compulsive behaviors among common neuropsychiatric features.
🧬

Genetic Associations

1
ALDH5A1 pathogenic variants
Autosomal recessive
💊

Treatments

2
Anticonvulsant therapy for seizures
Action: anticonvulsant agent therapy MAXO:0000167
Anticonvulsant treatment is symptom-directed management for SSADH-associated epileptic seizures rather than a proven correction of the enzyme defect; vigabatrin and tiagabine are generally avoided because they can further elevate GABA signaling.
Target Phenotypes: Bilateral tonic-clonic seizure ↗ Generalized myoclonic seizure ↗ Status epilepticus ↗
Show evidence (3 references)
PMID:38499966 SUPPORT Human Clinical
"Treatment was mainly aimed to control epileptic seizures and psychiatric symptoms."
Long-term registry cohort supports seizure-directed symptomatic treatment as current clinical management.
PMID:20301374 SUPPORT Other
"Vigabatrin may result in elevated gamma-aminobutyric acid (GABA) and exacerbation of manifestations, and its clinical utility has been inconsistent."
GeneReviews supports avoiding vigabatrin because it can elevate GABA and worsen manifestations.
PMID:20301374 SUPPORT Other
"Tiagabine could also lead to an increase in GABA levels and is not recommended for individuals with SSADH deficiency."
GeneReviews supports avoiding tiagabine because it can increase GABA levels.
Neuropsychiatric supportive care
Action: supportive care MAXO:0000950
Current management includes supportive treatment for psychiatric and behavioral symptoms, with no approved curative therapy for the underlying SSADH enzyme deficiency.
Target Phenotypes: Atypical behavior ↗ Autism ↗ Sleep disturbance ↗ Anxiety ↗ Obsessive-compulsive trait ↗ Attention problems ↗ Aggressive behavior ↗
Show evidence (2 references)
PMID:38499966 SUPPORT Human Clinical
"Treatment was mainly aimed to control epileptic seizures and psychiatric symptoms."
Long-term registry cohort supports supportive management of psychiatric symptoms.
PMID:32093054 SUPPORT Other
"Despite ambitious scientific effort, detailed knowledge about many aspects of the pathophysiology of the underlying enzyme defect is still lacking, and at present, no curative treatment that would directly target the enzyme deficiency is available for SSADH-D."
Review evidence supports limiting current treatment claims to symptomatic/supportive care.
🔬

Biochemical Markers

3
Elevated 4-hydroxybutyric acid (INCREASED)
Context: Elevated 4-hydroxybutyric acid/GHB in urine, CSF, plasma, or other body fluids is a hallmark biochemical feature and part of the diagnostic metabolic signature.
Pathograph Readouts
Readout Of GABA and 4-Hydroxybutyrate Accumulation Positive Diagnostic
Elevated GHB reports diversion of accumulated succinic semialdehyde to 4-hydroxybutyrate.
Show evidence (2 references)
PMID:31117962 SUPPORT Human Clinical
"Urine organic acid analysis revealed elevated GHB in all the patients."
Human case series documents elevated urinary GHB in all four diagnosed patients.
PMID:37455357 SUPPORT Human Clinical
"Targeted analysis of NGMS data from cerebrospinal fluid (CSF) showed a moderate increase of aspartic acid, glutaric acid, glycolic acid, 4-guanidinobutanoic acid, and 2-hydroxyglutaric acid, and prominent elevations of GHB and 4,5-dihydroxyhexanoic acid (4,5-DHHA) in SSADHD samples."
Patient metabolomics supports prominent GHB elevation in CSF.
Elevated gamma-aminobutyric acid (INCREASED)
Context: GABA accumulation reflects the upstream catabolic block and is part of the physiological-fluid metabolic signature.
Pathograph Readouts
Readout Of GABA and 4-Hydroxybutyrate Accumulation Positive Diagnostic
Elevated GABA reports the upstream neurotransmitter-catabolism block.
Show evidence (1 reference)
PMID:32967698 SUPPORT Human Clinical
"The metabolic signature includes elevated GHB and GABA in physiological fluids, among other metabolites [11]."
Human biomarker study directly supports elevated GABA as part of the metabolic signature.
Elevated 4,5-dihydroxyhexanoic acid (INCREASED)
Context: 4,5-dihydroxyhexanoic acid is an additional diagnostic biomarker elevated in SSADH deficiency body fluids and correlating with the broader GHB-linked metabolic signature.
Pathograph Readouts
Readout Of GABA and 4-Hydroxybutyrate Accumulation Positive Diagnostic
Elevated 4,5-DHHA reports succinic-semialdehyde-derived metabolite accumulation.
Show evidence (1 reference)
PMID:37455357 SUPPORT Human Clinical
"Targeted analysis of NGMS data from cerebrospinal fluid (CSF) showed a moderate increase of aspartic acid, glutaric acid, glycolic acid, 4-guanidinobutanoic acid, and 2-hydroxyglutaric acid, and prominent elevations of GHB and 4,5-dihydroxyhexanoic acid (4,5-DHHA) in SSADHD samples."
Patient CSF metabolomics supports prominent 4,5-DHHA elevation as part of the SSADH metabolic signature.
🔬

Clinical Trials

1
NCT02019667 PHASE_II COMPLETED
Randomized double-blind crossover phase II trial of the GABA-B receptor antagonist SGS-742 versus placebo; the trial did not improve adaptive behavior or cortical excitability measures.
Target Phenotypes: Intellectual disability ↗
Show evidence (3 references)
clinicaltrials:NCT02019667 SUPPORT Human Clinical
"To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency."
ClinicalTrials.gov documents the completed SGS-742 phase II trial design in SSADH deficiency.
PMID:34015244 SUPPORT Human Clinical
"This was a single-center randomized, double-blind crossover phase II clinical trial of SGS-742 versus placebo in patients with succinic semialdehyde dehydrogenase deficiency."
The publication identifies NCT02019667 as a randomized phase II SGS-742 trial in SSADH deficiency.
PMID:34015244 SUPPORT Human Clinical
"SGS-742 failed to produce improved cognition and normalization of cortical excitability as measured by the Adaptive Behavior Assessment Scale and transcranial magnetic stimulation."
The phase II trial result supports recording SGS-742 as a completed but negative disease-mechanism trial.
{ }

Source YAML

click to show 
name: Succinic Semialdehyde Dehydrogenase Deficiency
creation_date: "2026-05-11T09:21:23Z"
updated_date: "2026-05-21T11:46:20Z"
category: Mendelian
synonyms:
- 4-hydroxybutyric aciduria
- Gamma-hydroxybutyric aciduria
- SSADH deficiency
description: >-
  Succinic semialdehyde dehydrogenase deficiency is an autosomal recessive
  neurometabolic disorder of GABA metabolism caused by biallelic ALDH5A1
  pathogenic variants. The clinical spectrum ranges from mild to severe and
  commonly includes intellectual disability, developmental delay, hypotonia,
  ataxia, epilepsy, and behavioral dysregulation.
disease_term:
  preferred_term: succinic semialdehyde dehydrogenase deficiency
  term:
    id: MONDO:0010083
    label: succinic semialdehyde dehydrogenase deficiency
parents:
- gamma-amino butyric acid metabolism disorder
- Inborn error of metabolism
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010083
      label: succinic semialdehyde dehydrogenase deficiency
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: MONDO exact match for Orphanet ORPHA:22 and OMIM:271980.
prevalence:
- population: Worldwide
  percentage: "1-9 / 1 000 000"
  notes: Orphanet reports worldwide point prevalence between 1 and 9 per 1,000,000.
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | Worldwide | Point prevalence | PMID:34882073"
    explanation: Orphanet provides the worldwide point-prevalence estimate for SSADH deficiency.
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance for SSADH deficiency.
progression:
- phase: Variable infantile to childhood-onset neurometabolic disorder
  age_range: Neonatal period through childhood
  notes: >-
    Orphanet records neonatal, infantile, and childhood onset for SSADH
    deficiency, with clinical severity ranging from mild to severe.
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Neonatal"
    explanation: Orphanet records neonatal onset as part of the disease spectrum.
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Infancy"
    explanation: Orphanet records infantile onset as part of the disease spectrum.
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: Orphanet records childhood onset as part of the disease spectrum.
pathophysiology:
- name: ALDH5A1 Pathogenic Variants
  description: >-
    Biallelic ALDH5A1 pathogenic variants are the initiating molecular cause of
    SSADH deficiency.
  genes:
  - preferred_term: ALDH5A1
    term:
      id: hgnc:408
      label: ALDH5A1
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ALDH5A1 | aldehyde dehydrogenase 5 family member A1 | hgnc:408 | Disease-causing germline mutation(s) in"
    explanation: Orphanet identifies ALDH5A1 germline variants as disease causing in SSADH deficiency.
  - reference: PMID:39011401
    reference_title: "Succinic semialdehyde dehydrogenase deficiency: a metabolic and genomic approach to diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disorder is due to bi-allelic pathogenic variants in ALDH5A1 and is usually characterized by moderate-to-severe developmental delays, hypotonia, intellectual disability, ataxia, seizures, hyperkinetic behavior, aggression, psychiatric disorders, and sleep disturbances."
    explanation: A diagnostic cohort study directly links SSADH deficiency to biallelic ALDH5A1 pathogenic variants.
  downstream:
  - target: Succinate-Semialdehyde Dehydrogenase Catalytic Block
    causal_link_type: DIRECT
    description: ALDH5A1 encodes succinic semialdehyde dehydrogenase, so pathogenic variants reduce the enzyme's catalytic conversion of succinic semialdehyde to succinate.
    evidence:
    - reference: PMID:31117962
      reference_title: "Clinical diagnosis and mutation analysis of four Chinese families with succinic semialdehyde dehydrogenase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The absence of SSADH, which is encoded by aldehyde dehydrogenase family 5 member A1 (ALDH5A1) gene, leads to the accumulation of GABA and γ-hydroxybutyric acid (GHB)."
      explanation: Human case-series evidence connects ALDH5A1-encoded SSADH absence to downstream metabolite accumulation.
- name: Succinate-Semialdehyde Dehydrogenase Catalytic Block
  description: >-
    Loss of SSADH activity blocks the mitochondrial oxidation of succinic
    semialdehyde to succinate in the GABA catabolic pathway.
  molecular_functions:
  - preferred_term: succinate-semialdehyde dehydrogenase (NAD+) activity
    term:
      id: GO:0004777
      label: succinate-semialdehyde dehydrogenase (NAD+) activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: GABA metabolic process
    term:
      id: GO:0009448
      label: GABA metabolic process
    modifier: ABNORMAL
  - preferred_term: GABA catabolic process
    term:
      id: GO:0009450
      label: GABA catabolic process
    modifier: DECREASED
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  chemical_entities:
  - preferred_term: succinate semialdehyde
    term:
      id: CHEBI:57706
      label: 4-oxobutanoate
    modifier: INCREASED
  - preferred_term: succinate
    term:
      id: CHEBI:30031
      label: succinate(2-)
    modifier: DECREASED
  evidence:
  - reference: PMID:32967698
    reference_title: "Novel biomarkers and age-related metabolite correlations in plasma and dried blood spots from patients with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The product of glutamate decarboxylation, GABA is catabolized to succinic acid in a two-enzyme sequence, including generation of succinic semialdehyde (SSA) catalyzed by GABA-aminotransferase and the further oxidation of SSA to succinic acid catalyzed by SSADH [10]."
    explanation: Human biomarker-study background defines the blocked SSADH-catalyzed oxidation step.
  - reference: PMID:27896081
    reference_title: "Evidence of redox imbalance in a patient with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Succinic semialdehyde dehydrogenase (SSADH; EC 1.2.1.24) deficiency is a rare disorder (OMIM 271980) of γ-aminobutyric acid (GABA) degradation caused by mutations in ALDH5A1[1], [2]."
    explanation: Human case report supports ALDH5A1-driven SSADH deficiency as a GABA-degradation disorder.
  downstream:
  - target: GABA and 4-Hydroxybutyrate Accumulation
    causal_link_type: DIRECT
    description: When SSADH cannot oxidize succinic semialdehyde to succinate, GABA-pathway intermediates are diverted toward GHB and related metabolites.
    evidence:
    - reference: PMID:31117962
      reference_title: "Clinical diagnosis and mutation analysis of four Chinese families with succinic semialdehyde dehydrogenase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The absence of SSADH, which is encoded by aldehyde dehydrogenase family 5 member A1 (ALDH5A1) gene, leads to the accumulation of GABA and γ-hydroxybutyric acid (GHB)."
      explanation: Patient series directly links SSADH absence to GABA and GHB accumulation.
- name: GABA and 4-Hydroxybutyrate Accumulation
  description: >-
    Impaired GABA catabolism produces elevated GABA and 4-hydroxybutyrate/GHB in
    patient body fluids, with GHB and related metabolites forming a diagnostic
    metabolic signature.
  biological_processes:
  - preferred_term: GABA catabolic process
    term:
      id: GO:0009450
      label: GABA catabolic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: gamma-aminobutyric acid
    term:
      id: CHEBI:16865
      label: gamma-aminobutyric acid
    modifier: INCREASED
  - preferred_term: 4-hydroxybutyric acid
    term:
      id: CHEBI:30830
      label: 4-hydroxybutyric acid
    modifier: INCREASED
  evidence:
  - reference: PMID:37455357
    reference_title: "Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted analysis of NGMS data from cerebrospinal fluid (CSF) showed a moderate increase of aspartic acid, glutaric acid, glycolic acid, 4-guanidinobutanoic acid, and 2-hydroxyglutaric acid, and prominent elevations of GHB and 4,5-dihydroxyhexanoic acid (4,5-DHHA) in SSADHD samples."
    explanation: Patient metabolomics demonstrates prominent GHB and 4,5-DHHA elevations.
  - reference: PMID:32967698
    reference_title: "Novel biomarkers and age-related metabolite correlations in plasma and dried blood spots from patients with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The metabolic signature includes elevated GHB and GABA in physiological fluids, among other metabolites [11]."
    explanation: Human biomarker study summarizes the elevated GHB and GABA metabolic signature.
  downstream:
  - target: GABAergic Network Dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Excess GABA and GHB alter inhibitory neurotransmitter signaling and downstream synaptic physiology.
    description: Accumulated GABA-pathway metabolites perturb neuronal signaling in a disorder centered on GABAergic neurotransmission.
    evidence:
    - reference: PMID:35269750
      reference_title: "Understanding the Molecular Mechanisms of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD): Towards the Development of SSADH-Targeted Medicine."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Pathologic brain accumulation of GABA and γ-hydroxybutyrate (GHB), a neuroactive by-product of GABA catabolism, leads to a multitude of molecular abnormalities beginning in early life, culminating in multifaceted clinical presentations including delayed psychomotor development, intellectual disability, hypotonia, and ataxia."
      explanation: Mechanism review links pathologic GABA and GHB accumulation to early molecular abnormalities and neurodevelopmental phenotypes.
  - target: Basal Ganglia Vulnerability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - excess GABA and GHB exposure in basal ganglia circuits
    description: GABA/GHB accumulation affects basal ganglia-rich neural circuits, consistent with globus pallidus neuropathology and MRI abnormalities.
    evidence:
    - reference: PMID:31117962
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cerebral MRI showed symmetrical hyperintense signal of bilateral globus pallidus and basal ganglia in patient 1"
      explanation: Human MRI evidence supports basal ganglia and globus pallidus involvement downstream of SSADH deficiency.
  - target: Abnormality of metabolism/homeostasis
    causal_link_type: DIRECT
    description: Elevated GABA, GHB, and related metabolites constitute the core metabolic homeostasis abnormality in SSADH deficiency.
    evidence:
    - reference: ORPHA:22
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001939 | Abnormality of metabolism/homeostasis | Very frequent (99-80%)"
      explanation: Orphanet records abnormal metabolism/homeostasis as a very frequent SSADH deficiency phenotype.
  - target: Elevated 4-hydroxybutyric acid
    causal_link_type: DIRECT
    description: SSADH deficiency elevates GHB/4-hydroxybutyric acid as a core diagnostic metabolite.
    evidence:
    - reference: PMID:31117962
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Urine organic acid analysis revealed elevated GHB in all the patients."
      explanation: Human case-series evidence supports elevated GHB/4-hydroxybutyric acid as a biochemical readout of metabolite accumulation.
  - target: Elevated gamma-aminobutyric acid
    causal_link_type: DIRECT
    description: Impaired GABA catabolism elevates GABA in physiological fluids.
    evidence:
    - reference: PMID:32967698
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The metabolic signature includes elevated GHB and GABA in physiological fluids, among other metabolites [11]."
      explanation: Human biomarker evidence supports elevated GABA as part of the SSADH metabolic signature.
  - target: Elevated 4,5-dihydroxyhexanoic acid
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - succinic-semialdehyde-derived metabolite accumulation
    description: Untargeted and targeted metabolomics show 4,5-DHHA elevation alongside GHB in SSADH deficiency.
    evidence:
    - reference: PMID:37455357
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Targeted analysis of NGMS data from cerebrospinal fluid (CSF) showed a moderate increase of aspartic acid, glutaric acid, glycolic acid, 4-guanidinobutanoic acid, and 2-hydroxyglutaric acid, and prominent elevations of GHB and 4,5-dihydroxyhexanoic acid (4,5-DHHA) in SSADHD samples."
      explanation: Patient CSF metabolomics supports 4,5-DHHA as a biochemical readout of the SSADH metabolite signature.
  - target: Oxidative and Mitochondrial Stress
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Accumulated GHB and reactive succinic semialdehyde can contribute to oxidative stress and mitochondrial dysfunction.
    description: Metabolite accumulation is associated with redox imbalance and mitochondrial dysfunction in patient and model evidence.
    evidence:
    - reference: PMID:27896081
      reference_title: "Evidence of redox imbalance in a patient with succinic semialdehyde dehydrogenase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We report on a patient with early-onset SSADH deficiency for which we demonstrate persistently low GSH levels and abnormal elevations of some dicarboxylic acids in urine suggesting possible redox imbalance and/or mitochondrial dysfunction."
      explanation: Human case evidence supports redox imbalance and possible mitochondrial dysfunction in SSADH deficiency.
- name: Basal Ganglia Vulnerability
  description: >-
    GABA-rich basal ganglia structures, especially the globus pallidus, are a
    recurrent neuroanatomical focus in SSADH deficiency, linking the metabolic
    neurotransmitter defect to movement features and characteristic MRI signal
    abnormalities.
  locations:
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  - preferred_term: globus pallidus
    term:
      id: UBERON:0001875
      label: globus pallidus
  biological_processes:
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: ABNORMAL
  evidence:
  - reference: PMID:31117962
    reference_title: "Clinical diagnosis and mutation analysis of four Chinese families with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebral MRI showed symmetrical hyperintense signal of bilateral globus pallidus and basal ganglia in patient 1"
    explanation: Human case-series evidence documents globus-pallidus and basal-ganglia involvement on MRI.
  downstream:
  - target: Focal T2 hyperintense basal ganglia lesion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - globus pallidus involvement
    - basal ganglia signal abnormality
    description: Basal ganglia vulnerability is reflected by recurrent globus-pallidus and basal-ganglia T2 hyperintensity on MRI.
    evidence:
    - reference: PMID:31117962
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cerebral MRI showed symmetrical hyperintense signal of bilateral globus pallidus and basal ganglia in patient 1"
      explanation: Human MRI evidence directly supports basal-ganglia/globus-pallidus hyperintensity.
  - target: Dystonia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - basal ganglia circuit dysfunction
    description: Basal ganglia circuit involvement can contribute to dystonia within the SSADH movement-disorder spectrum.
    evidence:
    - reference: PMID:38499966
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "After ataxia, dystonia (19%), chorea (11%) and hypokinesia (15%) were the most frequent movement disorders."
      explanation: Registry follow-up data support dystonia as part of the SSADH movement-disorder spectrum.
  - target: Chorea
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - basal ganglia circuit dysfunction
    description: Basal ganglia circuit involvement can contribute to chorea within the SSADH movement-disorder spectrum.
    evidence:
    - reference: PMID:38499966
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "After ataxia, dystonia (19%), chorea (11%) and hypokinesia (15%) were the most frequent movement disorders."
      explanation: Registry follow-up data support chorea as part of the SSADH movement-disorder spectrum.
  - target: Exertional dyskinesia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - basal ganglia circuit dysfunction
    description: Basal ganglia circuit involvement can contribute to exertional dyskinesia within the SSADH movement-disorder spectrum.
    evidence:
    - reference: PMID:20301374
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
      explanation: GeneReviews lists exertional dyskinesia among SSADH deficiency movement manifestations.
- name: GABAergic Network Dysfunction
  description: >-
    Patient-derived GABAergic neuronal models and longitudinal human data
    support altered inhibitory/excitatory signaling as a contributor to
    epilepsy, developmental delay, movement features, sleep disturbance, and
    psychiatric manifestations.
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: ABNORMAL
  - preferred_term: synaptic transmission, glutamatergic
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
    modifier: INCREASED
  evidence:
  - reference: PMID:38658850
    reference_title: "Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autism, epilepsy, movement disorders, sleep disturbances, and various psychiatric behaviors constituted the core of the disorder's clinical phenotype."
    explanation: Natural-history cohort evidence defines the major neurologic and neuropsychiatric phenotype cluster.
  - reference: PMID:38658850
    reference_title: "Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "iPSCs, which were differentiated into GABAergic neurons, represent the first in vitro neuronal model of SSADHD and express the neuronal marker microtubule-associated protein 2 (MAP2), as well as GABA."
    explanation: Patient-derived in vitro GABAergic neurons support a neuronal model for the signaling mechanism.
  - reference: PMID:38658850
    reference_title: "Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "GABA-metabolism in induced GABAergic neurons could be reversed using CRISPR correction of the pathogenic variants or mRNA transfection and SSADHD iPSCs were associated with excessive glutamatergic activity and related synaptic excitation."
    explanation: Patient-derived neuronal models support increased glutamatergic synaptic excitation downstream of the SSADH metabolic defect.
  downstream:
  - target: Intellectual disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: GABAergic network dysfunction contributes to impaired neurocognitive development.
    evidence:
    - reference: ORPHA:22
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001249 | Intellectual disability | Very frequent (99-80%)"
      explanation: Orphanet lists intellectual disability as a very frequent SSADH deficiency phenotype.
  - target: Global developmental delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Altered early-life inhibitory signaling contributes to developmental delay.
    evidence:
    - reference: ORPHA:22
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001263 | Global developmental delay | Very frequent (99-80%)"
      explanation: Orphanet lists global developmental delay as a very frequent SSADH deficiency phenotype.
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Neurodevelopmental network dysfunction contributes to low muscle tone.
    evidence:
    - reference: ORPHA:22
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001252 | Hypotonia | Very frequent (99-80%)"
      explanation: Orphanet lists hypotonia as a very frequent SSADH deficiency phenotype.
  - target: Ataxia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Central nervous system dysfunction contributes to impaired coordination.
    evidence:
    - reference: ORPHA:22
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001251 | Ataxia | Very frequent (99-80%)"
      explanation: Orphanet lists ataxia as a very frequent SSADH deficiency phenotype.
  - target: Bilateral tonic-clonic seizure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Altered neuronal excitability contributes to epilepsy and convulsive seizures.
    evidence:
    - reference: ORPHA:22
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002069 | Bilateral tonic-clonic seizure | Frequent (79-30%)"
      explanation: Orphanet lists bilateral tonic-clonic seizures as a frequent SSADH deficiency phenotype.
  - target: Status epilepticus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Severe seizure susceptibility can progress to prolonged seizures.
    evidence:
    - reference: ORPHA:22
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002133 | Status epilepticus | Frequent (79-30%)"
      explanation: Orphanet lists status epilepticus as a frequent SSADH deficiency phenotype.
  - target: Generalized myoclonic seizure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Altered neuronal excitability contributes to generalized myoclonic seizures.
    evidence:
    - reference: ORPHA:22
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002123 | Generalized myoclonic seizure | Frequent (79-30%)"
      explanation: Orphanet lists generalized myoclonic seizures as a frequent SSADH deficiency phenotype.
  - target: Sudden unexpected death in epilepsy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - epilepsy
    description: The epilepsy phenotype carries a recognized SUDEP risk in SSADH deficiency.
    evidence:
    - reference: PMID:35269750
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Paradoxically, over half of patients with SSADHD also develop epilepsy and face a significant risk of sudden unexpected death in epilepsy (SUDEP)."
      explanation: Mechanism review evidence links SSADH-associated epilepsy to SUDEP risk.
  - target: Expressive language delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Early-life neurotransmitter network dysfunction contributes to prominent language-development delay.
    evidence:
    - reference: PMID:38658850
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Language developmental delays were more prominent than motor."
      explanation: Natural-history cohort evidence supports expressive-language delay as a prominent SSADH deficiency phenotype.
  - target: Sleep disturbance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: GABAergic network dysfunction contributes to sleep dysregulation.
    evidence:
    - reference: PMID:38658850
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Autism, epilepsy, movement disorders, sleep disturbances, and various psychiatric behaviors constituted the core of the disorder's clinical phenotype."
      explanation: Natural-history cohort evidence identifies sleep disturbance as part of the core phenotype.
  - target: Autism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Altered inhibitory and excitatory signaling contributes to autistic features in the core neurodevelopmental phenotype.
    evidence:
    - reference: PMID:38658850
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Autism, epilepsy, movement disorders, sleep disturbances, and various psychiatric behaviors constituted the core of the disorder's clinical phenotype."
      explanation: Natural-history cohort evidence identifies autism as part of the core phenotype.
  - target: Atypical behavior
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Neurodevelopmental network dysfunction contributes to behavioral dysregulation.
    evidence:
    - reference: ORPHA:22
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000708 | Atypical behavior | Frequent (79-30%)"
      explanation: Orphanet lists atypical behavior as a frequent SSADH deficiency phenotype.
  - target: Anxiety
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: GABAergic network dysfunction contributes to anxiety in the neuropsychiatric phenotype.
    evidence:
    - reference: PMID:20301374
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
      explanation: GeneReviews lists anxiety among SSADH deficiency neuropsychiatric manifestations.
  - target: Obsessive-compulsive trait
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Altered inhibitory signaling contributes to obsessive-compulsive behaviors in the neuropsychiatric phenotype.
    evidence:
    - reference: PMID:20301374
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
      explanation: GeneReviews lists obsessive-compulsive behaviors among SSADH deficiency neuropsychiatric manifestations.
  - target: Attention deficit hyperactivity disorder
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: GABAergic network dysfunction contributes to short attention span and distractibility in the behavioral phenotype.
    evidence:
    - reference: PMID:20301374
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
      explanation: GeneReviews lists attention problems among SSADH deficiency neuropsychiatric manifestations.
  - target: Aggressive behavior
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Neuropsychiatric dysregulation can include aggression and related behavioral symptoms.
    evidence:
    - reference: PMID:39011401
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The disorder is due to bi-allelic pathogenic variants in ALDH5A1 and is usually characterized by moderate-to-severe developmental delays, hypotonia, intellectual disability, ataxia, seizures, hyperkinetic behavior, aggression, psychiatric disorders, and sleep disturbances."
      explanation: Diagnostic cohort evidence lists aggression among typical SSADH deficiency manifestations.
- name: Oxidative and Mitochondrial Stress
  description: >-
    SSADH deficiency can include redox imbalance and mitochondrial dysfunction,
    shown in a human patient by persistently low glutathione and abnormal urinary
    dicarboxylic acids and supported by model evidence.
  biological_processes:
  - preferred_term: reactive oxygen species metabolic process
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
    modifier: ABNORMAL
  chemical_entities:
  - preferred_term: glutathione
    term:
      id: CHEBI:16856
      label: glutathione
    modifier: DECREASED
  evidence:
  - reference: PMID:27896081
    reference_title: "Evidence of redox imbalance in a patient with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The GSH level in our patient was 585 μM at age 5 months, 702 μM at age 9 months, and 698 μM at age 10 months (controls: 900 μM ± 140, n = 59)."
    explanation: Direct patient measurements document low glutathione as a redox-stress marker.
phenotypes:
- name: Intellectual disability
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001249 | Intellectual disability | Very frequent (99-80%)"
    explanation: Orphanet lists intellectual disability as a very frequent phenotype.
- name: Ataxia
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001251 | Ataxia | Very frequent (99-80%)"
    explanation: Orphanet lists ataxia as a very frequent phenotype.
- name: Hypotonia
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001252 | Hypotonia | Very frequent (99-80%)"
    explanation: Orphanet lists hypotonia as a very frequent phenotype.
- name: Global developmental delay
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001263 | Global developmental delay | Very frequent (99-80%)"
    explanation: Orphanet lists global developmental delay as a very frequent phenotype.
- name: Abnormality of metabolism/homeostasis
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Abnormality of metabolism/homeostasis
    term:
      id: HP:0001939
      label: Abnormality of metabolism/homeostasis
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001939 | Abnormality of metabolism/homeostasis | Very frequent (99-80%)"
    explanation: Orphanet lists abnormal metabolism or homeostasis as a very frequent phenotype.
- name: Atypical behavior
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000708 | Atypical behavior | Frequent (79-30%)"
    explanation: Orphanet lists atypical behavior as a frequent phenotype.
- name: Bilateral tonic-clonic seizure
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002069 | Bilateral tonic-clonic seizure | Frequent (79-30%)"
    explanation: Orphanet lists bilateral tonic-clonic seizure as a frequent phenotype.
- name: Generalized myoclonic seizure
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Generalized myoclonic seizure
    term:
      id: HP:0002123
      label: Generalized myoclonic seizure
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002123 | Generalized myoclonic seizure | Frequent (79-30%)"
    explanation: Orphanet lists generalized myoclonic seizure as a frequent phenotype.
- name: Status epilepticus
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002133 | Status epilepticus | Frequent (79-30%)"
    explanation: Orphanet lists status epilepticus as a frequent phenotype.
- name: Sudden unexpected death in epilepsy
  phenotype_term:
    preferred_term: Sudden unexpected death in epilepsy
    term:
      id: HP:0033258
      label: Sudden unexpected death in epilepsy
  evidence:
  - reference: PMID:35269750
    reference_title: "Understanding the Molecular Mechanisms of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD): Towards the Development of SSADH-Targeted Medicine."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Paradoxically, over half of patients with SSADHD also develop epilepsy and face a significant risk of sudden unexpected death in epilepsy (SUDEP)."
    explanation: Mechanism review identifies SUDEP as a clinically significant epilepsy-related complication.
- name: Focal T2 hyperintense basal ganglia lesion
  phenotype_term:
    preferred_term: Bilateral globus pallidus and basal ganglia T2 hyperintensity
    term:
      id: HP:0007183
      label: Focal T2 hyperintense basal ganglia lesion
  evidence:
  - reference: PMID:31117962
    reference_title: "Clinical diagnosis and mutation analysis of four Chinese families with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebral MRI showed symmetrical hyperintense signal of bilateral globus pallidus and basal ganglia in patient 1"
    explanation: Human case series documents basal-ganglia/globus-pallidus MRI hyperintensity in SSADH deficiency.
- name: Expressive language delay
  phenotype_term:
    preferred_term: Expressive language delay
    term:
      id: HP:0002474
      label: Expressive language delay
  evidence:
  - reference: ORPHA:22
    reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare neurometabolic disorder of gamma-aminobutyric acid (GABA) metabolism with a nonspecific clinical presentation (ranging from mild to severe) with the most frequent symptoms being cognitive impairment with prominent deficit in expressive language, hypotonia, ataxia, epilepsy, and behavioral dysregulation."
    explanation: Orphanet's definition identifies prominent expressive-language deficit as a frequent clinical feature.
  - reference: PMID:38658850
    reference_title: "Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Language developmental delays were more prominent than motor."
    explanation: The 62-subject natural-history cohort supports language delay as a prominent phenotype.
- name: Sleep disturbance
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:38658850
    reference_title: "Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autism, epilepsy, movement disorders, sleep disturbances, and various psychiatric behaviors constituted the core of the disorder's clinical phenotype."
    explanation: The natural-history cohort identifies sleep disturbance as part of the core phenotype.
- name: Autism
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:38658850
    reference_title: "Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autism, epilepsy, movement disorders, sleep disturbances, and various psychiatric behaviors constituted the core of the disorder's clinical phenotype."
    explanation: The natural-history cohort identifies autism as part of the core phenotype.
- name: Dystonia
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:38499966
    reference_title: "The continuously evolving phenotype of succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After ataxia, dystonia (19%), chorea (11%) and hypokinesia (15%) were the most frequent movement disorders."
    explanation: Registry follow-up data identify dystonia as a recurrent movement phenotype.
  - reference: PMID:20301374
    reference_title: "Succinic Semialdehyde Dehydrogenase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
    explanation: GeneReviews lists dystonia among common movement-disorder manifestations.
- name: Chorea
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  evidence:
  - reference: PMID:38499966
    reference_title: "The continuously evolving phenotype of succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After ataxia, dystonia (19%), chorea (11%) and hypokinesia (15%) were the most frequent movement disorders."
    explanation: Registry follow-up data identify chorea as a recurrent movement phenotype.
- name: Exertional dyskinesia
  phenotype_term:
    preferred_term: Exertional dyskinesia
    term:
      id: HP:0100660
      label: Dyskinesia
  evidence:
  - reference: PMID:20301374
    reference_title: "Succinic Semialdehyde Dehydrogenase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
    explanation: GeneReviews lists exertional dyskinesia among common movement-disorder manifestations.
- name: Anxiety
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:20301374
    reference_title: "Succinic Semialdehyde Dehydrogenase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
    explanation: GeneReviews lists anxiety among common neuropsychiatric features.
- name: Obsessive-compulsive trait
  phenotype_term:
    preferred_term: Obsessive-compulsive trait
    term:
      id: HP:0008770
      label: Obsessive-compulsive trait
  evidence:
  - reference: PMID:20301374
    reference_title: "Succinic Semialdehyde Dehydrogenase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
    explanation: GeneReviews lists obsessive-compulsive behaviors among common neuropsychiatric features.
- name: Attention deficit hyperactivity disorder
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Attention problems
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: PMID:38499966
    reference_title: "The continuously evolving phenotype of succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Short attention span (78.6%) and distractibility (71.4%) were the most frequently behavior traits mentioned by parents"
    explanation: Registry follow-up data support frequent attention problems, represented with the closest HPO attention-deficit term.
  - reference: PMID:20301374
    reference_title: "Succinic Semialdehyde Dehydrogenase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "movement disorders (such as ataxia, dystonia, and exertional dyskinesia), sleep disturbances, attention problems, anxiety, and obsessive-compulsive behaviors."
    explanation: GeneReviews lists attention problems among common neuropsychiatric features.
- name: Aggressive behavior
  phenotype_term:
    preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: PMID:39011401
    reference_title: "Succinic semialdehyde dehydrogenase deficiency: a metabolic and genomic approach to diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disorder is due to bi-allelic pathogenic variants in ALDH5A1 and is usually characterized by moderate-to-severe developmental delays, hypotonia, intellectual disability, ataxia, seizures, hyperkinetic behavior, aggression, psychiatric disorders, and sleep disturbances."
    explanation: Diagnostic cohort summary includes aggression in the typical SSADH phenotype.
biochemical:
- name: Elevated 4-hydroxybutyric acid
  presence: INCREASED
  context: >-
    Elevated 4-hydroxybutyric acid/GHB in urine, CSF, plasma, or other body
    fluids is a hallmark biochemical feature and part of the diagnostic
    metabolic signature.
  biomarker_term:
    preferred_term: 4-hydroxybutyric acid
    term:
      id: CHEBI:30830
      label: 4-hydroxybutyric acid
  readouts:
  - target: GABA and 4-Hydroxybutyrate Accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated GHB reports diversion of accumulated succinic semialdehyde to 4-hydroxybutyrate.
  evidence:
  - reference: PMID:31117962
    reference_title: "Clinical diagnosis and mutation analysis of four Chinese families with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Urine organic acid analysis revealed elevated GHB in all the patients."
    explanation: Human case series documents elevated urinary GHB in all four diagnosed patients.
  - reference: PMID:37455357
    reference_title: "Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted analysis of NGMS data from cerebrospinal fluid (CSF) showed a moderate increase of aspartic acid, glutaric acid, glycolic acid, 4-guanidinobutanoic acid, and 2-hydroxyglutaric acid, and prominent elevations of GHB and 4,5-dihydroxyhexanoic acid (4,5-DHHA) in SSADHD samples."
    explanation: Patient metabolomics supports prominent GHB elevation in CSF.
- name: Elevated gamma-aminobutyric acid
  presence: INCREASED
  context: >-
    GABA accumulation reflects the upstream catabolic block and is part of the
    physiological-fluid metabolic signature.
  biomarker_term:
    preferred_term: gamma-aminobutyric acid
    term:
      id: CHEBI:16865
      label: gamma-aminobutyric acid
  readouts:
  - target: GABA and 4-Hydroxybutyrate Accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated GABA reports the upstream neurotransmitter-catabolism block.
  evidence:
  - reference: PMID:32967698
    reference_title: "Novel biomarkers and age-related metabolite correlations in plasma and dried blood spots from patients with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The metabolic signature includes elevated GHB and GABA in physiological fluids, among other metabolites [11]."
    explanation: Human biomarker study directly supports elevated GABA as part of the metabolic signature.
- name: Elevated 4,5-dihydroxyhexanoic acid
  presence: INCREASED
  context: >-
    4,5-dihydroxyhexanoic acid is an additional diagnostic biomarker elevated
    in SSADH deficiency body fluids and correlating with the broader GHB-linked
    metabolic signature.
  readouts:
  - target: GABA and 4-Hydroxybutyrate Accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated 4,5-DHHA reports succinic-semialdehyde-derived metabolite accumulation.
  evidence:
  - reference: PMID:37455357
    reference_title: "Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted analysis of NGMS data from cerebrospinal fluid (CSF) showed a moderate increase of aspartic acid, glutaric acid, glycolic acid, 4-guanidinobutanoic acid, and 2-hydroxyglutaric acid, and prominent elevations of GHB and 4,5-dihydroxyhexanoic acid (4,5-DHHA) in SSADHD samples."
    explanation: Patient CSF metabolomics supports prominent 4,5-DHHA elevation as part of the SSADH metabolic signature.
diagnosis:
- name: Urinary organic acid and GHB metabolite testing
  description: >-
    Urinary organic acid analysis detects elevated GHB and 4,5-DHHA, supporting
    biochemical diagnosis before or alongside molecular confirmation.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:31117962
    reference_title: "Clinical diagnosis and mutation analysis of four Chinese families with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CONCLUSION: SSADH deficiency is diagnosed based on the elevated GHB and 4, 5DHHA by urinary organic acid analysis."
    explanation: Case series conclusion directly supports urinary organic acid detection of GHB and 4,5-DHHA for diagnosis.
  - reference: PMID:27896081
    reference_title: "Evidence of redox imbalance in a patient with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of SSADH deficiency is based on detecting elevated levels of 4-hydroxybutyric and related metabolites in body fluids including urine [3], [4]."
    explanation: Human case report background supports 4-hydroxybutyric-acid metabolite detection as the diagnostic biochemical approach.
- name: ALDH5A1 molecular genetic testing
  description: >-
    Sequencing ALDH5A1 confirms biallelic pathogenic variants and complements
    the metabolomic signature in patients with nonspecific neurodevelopmental
    presentations.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:39011401
    reference_title: "Succinic semialdehyde dehydrogenase deficiency: a metabolic and genomic approach to diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we utilized an integrated approach to diagnosis of SSADHD by examining molecular, clinical, and metabolomic data from a single large commercial laboratory."
    explanation: Diagnostic study supports integrating molecular and metabolomic data for SSADH deficiency diagnosis.
  - reference: PMID:31117962
    reference_title: "Clinical diagnosis and mutation analysis of four Chinese families with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our study expands the mutation spectrum of ALDH5A1 and highlights the importance of molecular genetic evaluation in patients with SSADH deficiency."
    explanation: Human case series supports ALDH5A1 molecular evaluation in suspected SSADH deficiency.
- name: Brain MRI for basal ganglia signal abnormality
  description: >-
    Brain MRI can show bilateral globus pallidus and basal ganglia
    hyperintensity, supporting neuroimaging recognition of SSADH deficiency in
    patients with developmental delay or seizures.
  diagnosis_term:
    preferred_term: MRI of the brain
    term:
      id: MAXO:0000427
      label: MRI of the brain
  evidence:
  - reference: PMID:31117962
    reference_title: "Clinical diagnosis and mutation analysis of four Chinese families with succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebral MRI showed symmetrical hyperintense signal of bilateral globus pallidus and basal ganglia in patient 1; hyperintensity of bilateral frontal-parietal lobe, widened ventricle and sulci in patient 2; and widened ventricle and sulci in patient 4."
    explanation: Human case series supports brain MRI as a diagnostic adjunct and documents the basal-ganglia/globus-pallidus signal finding.
treatments:
- name: Anticonvulsant therapy for seizures
  description: >-
    Anticonvulsant treatment is symptom-directed management for SSADH-associated
    epileptic seizures rather than a proven correction of the enzyme defect;
    vigabatrin and tiagabine are generally avoided because they can further
    elevate GABA signaling.
  treatment_term:
    preferred_term: anticonvulsant agent therapy
    term:
      id: MAXO:0000167
      label: anticonvulsant agent therapy
  target_phenotypes:
  - preferred_term: Bilateral tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  - preferred_term: Generalized myoclonic seizure
    term:
      id: HP:0002123
      label: Generalized myoclonic seizure
  - preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: PMID:38499966
    reference_title: "The continuously evolving phenotype of succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment was mainly aimed to control epileptic seizures and psychiatric symptoms."
    explanation: Long-term registry cohort supports seizure-directed symptomatic treatment as current clinical management.
  - reference: PMID:20301374
    reference_title: "Succinic Semialdehyde Dehydrogenase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Vigabatrin may result in elevated gamma-aminobutyric acid (GABA) and exacerbation of manifestations, and its clinical utility has been inconsistent."
    explanation: GeneReviews supports avoiding vigabatrin because it can elevate GABA and worsen manifestations.
  - reference: PMID:20301374
    reference_title: "Succinic Semialdehyde Dehydrogenase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Tiagabine could also lead to an increase in GABA levels and is not recommended for individuals with SSADH deficiency."
    explanation: GeneReviews supports avoiding tiagabine because it can increase GABA levels.
- name: Neuropsychiatric supportive care
  description: >-
    Current management includes supportive treatment for psychiatric and
    behavioral symptoms, with no approved curative therapy for the underlying
    SSADH enzyme deficiency.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  - preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  - preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  - preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  - preferred_term: Obsessive-compulsive trait
    term:
      id: HP:0008770
      label: Obsessive-compulsive trait
  - preferred_term: Attention problems
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  - preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: PMID:38499966
    reference_title: "The continuously evolving phenotype of succinic semialdehyde dehydrogenase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment was mainly aimed to control epileptic seizures and psychiatric symptoms."
    explanation: Long-term registry cohort supports supportive management of psychiatric symptoms.
  - reference: PMID:32093054
    reference_title: "Succinic Semialdehyde Dehydrogenase Deficiency: An Update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Despite ambitious scientific effort, detailed knowledge about many aspects of the pathophysiology of the underlying enzyme defect is still lacking, and at present, no curative treatment that would directly target the enzyme deficiency is available for SSADH-D."
    explanation: Review evidence supports limiting current treatment claims to symptomatic/supportive care.
clinical_trials:
- name: NCT02019667
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Randomized double-blind crossover phase II trial of the GABA-B receptor
    antagonist SGS-742 versus placebo; the trial did not improve adaptive
    behavior or cortical excitability measures.
  target_phenotypes:
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: clinicaltrials:NCT02019667
    reference_title: "Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency."
    explanation: ClinicalTrials.gov documents the completed SGS-742 phase II trial design in SSADH deficiency.
  - reference: PMID:34015244
    reference_title: "A Randomized Controlled Trial of SGS-742, a γ-aminobutyric acid B (GABA-B) Receptor Antagonist, for Succinic Semialdehyde Dehydrogenase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This was a single-center randomized, double-blind crossover phase II clinical trial of SGS-742 versus placebo in patients with succinic semialdehyde dehydrogenase deficiency."
    explanation: The publication identifies NCT02019667 as a randomized phase II SGS-742 trial in SSADH deficiency.
  - reference: PMID:34015244
    reference_title: "A Randomized Controlled Trial of SGS-742, a γ-aminobutyric acid B (GABA-B) Receptor Antagonist, for Succinic Semialdehyde Dehydrogenase Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SGS-742 failed to produce improved cognition and normalization of cortical excitability as measured by the Adaptive Behavior Assessment Scale and transcranial magnetic stimulation."
    explanation: The phase II trial result supports recording SGS-742 as a completed but negative disease-mechanism trial.
genetic:
- name: ALDH5A1 pathogenic variants
  gene_term:
    preferred_term: ALDH5A1
    term:
      id: hgnc:408
      label: ALDH5A1
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: ORPHA:22
      reference_title: "Succinic semialdehyde dehydrogenase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "ALDH5A1 | aldehyde dehydrogenase 5 family member A1 | hgnc:408 | Disease-causing germline mutation(s) in"
      explanation: Orphanet records ALDH5A1 germline variants as disease causing.
references:
- reference: PMID:20301374
  title: "Succinic Semialdehyde Dehydrogenase Deficiency."
  tags:
  - GeneReviews
  findings: []
- reference: PMID:34015244
  title: "A Randomized Controlled Trial of SGS-742, a γ-aminobutyric acid B (GABA-B) Receptor Antagonist, for Succinic Semialdehyde Dehydrogenase Deficiency."
  found_in:
  - Succinic_Semialdehyde_Dehydrogenase_Deficiency-deep-research-asta.md
  findings: []
📚

References & Deep Research

References

2
PMID:20301374
Succinic Semialdehyde Dehydrogenase Deficiency.
No top-level findings curated for this source.
PMID:34015244
A Randomized Controlled Trial of SGS-742, a γ-aminobutyric acid B (GABA-B) Receptor Antagonist, for Succinic Semialdehyde Dehydrogenase Deficiency.
No top-level findings curated for this source.

Deep Research

1
Asta ▸
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Succinic Semialdehyde Dehydrogenase Deficiency. Core disease mechanisms, m...
Asta Scientific Corpus Retrieval 16 citations 2026-05-11T02:36:59.316006

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Succinic Semialdehyde Dehydrogenase Deficiency. Core disease mechanisms, m...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 16
  • Snippets retrieved: 20

Relevant Papers

[1] Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder

  • Authors: Itay Tokatly Latzer, J. Roullet, Wardiya Afshar-Saber, Henry H. C. Lee, M. Bertoldi et al.
  • Year: 2024
  • Venue: Journal of Neurodevelopmental Disorders
  • URL: https://www.semanticscholar.org/paper/e7c08a57fe45fd8fdf4db00d75ce5e933865ab66
  • DOI: 10.1186/s11689-024-09538-9
  • PMID: 38658850
  • PMCID: 11044349
  • Citations: 10
  • Summary: While epilepsy and psychiatric behaviors increase in severity with age, communication abilities and motor function tend to improve, and this further enables the identification of biomarkers and changes throughout development that will be essential for upcoming targeted trials of enzyme replacement and gene therapy.
  • Evidence snippets:
  • Snippet 1 (score: 0.696) > Succinic semialdehyde dehydrogenase deficiency (SSADHD) (OMIM #271,980) is an autosomal recessive inherited metabolic disorder of γ-aminobutyric acid (GABA) catabolism with an estimated pan-ethnic prevalence of ∼ 1/460,000 [1]. It was first postulated that SSADH deficiency leads to increased excretion of γ-hydroxybutyrate (GHB) and the associated neurological and developmental abnormalities in 1981 [2]. During the following decades, multiple case reports and laboratory-based studies established the evidence that the primary metabolic defect of SSADHD involves the GABA degradation pathway [3][4][5][6][7][8][9][10][11][12][13]. Deficiency or absence of SSADH, a mitochondrial enzyme, ensues in the accumulation of GABA and other metabolites such as GHB (Fig. 1). The genetic basis of SSADHD was first reported in 1998 [14], and since then, a number of case series and cohort studies have described the clinical and biochemical phenotypes of SSADHD resulting from biallelic pathogenic variants in ALDH5A1 [15][16][17][18][19][20]. Since different combinations of ALDH5A1 variants may ensue in variable structural and functional impairments of the resultant SSADH enzyme, the clinical presentation of SSADHD is broad in the degree of severity [21,22]. Considering the dominant presence of GABA in the basal ganglia, neuropathological findings of striking discoloration of the globus pallidi [23] and neuroimaging findings of (MRI)-derived T2-weighted hyperintensity in the globus pallidi and subthalamic nuclei, along with magnetic resonance spectroscopy (MRS)-derived increased GABA/N-acetylaspartate (NAA) ratios [24], suggest this is one of the primary areas involved in the clinical manifestations of the disorder.
  • Snippet 2 (score: 0.504) > Succinic semialdehyde dehydrogenase deficiency (SSADHD) represents a model neurometabolic disease at the fulcrum of translational research within the Boston Children’s Hospital Intellectual and Developmental Disabilities Research Centers (IDDRC), including the NIH-sponsored natural history study of clinical, neurophysiological, neuroimaging, and molecular markers, patient-derived induced pluripotent stem cells (iPSC) characterization, and development of a murine model for tightly regulated, cell-specific gene therapy. SSADHD subjects underwent clinical evaluations, neuropsychological assessments, biochemical quantification of γ-aminobutyrate (GABA) and related metabolites, electroencephalography (standard and high density), magnetoencephalography, transcranial magnetic stimulation, magnetic resonance imaging and spectroscopy, and genetic tests. This was parallel to laboratory molecular investigations of in vitro GABAergic neurons derived from induced human pluripotent stem cells (hiPSCs) of SSADHD subjects and biochemical analyses performed on a versatile murine model that uses an inducible and reversible rescue strategy allowing on-demand and cell-specific gene therapy. The 62 SSADHD subjects [53% females, median (IQR) age of 9.6 (5.4–14.5) years] included in the study had a reported symptom onset at ∼ 6 months and were diagnosed at a median age of 4 years. Language developmental delays were more prominent than motor. Autism, epilepsy, movement disorders, sleep disturbances, and various psychiatric behaviors constituted the core of the disorder’s clinical phenotype. Lower clinical severity scores, indicating worst severity, coincided with older age (R= -0.302, p = 0.03), as well as age-adjusted lower values of plasma γ-aminobutyrate (GABA) (R = 0.337, p = 0.02) and γ-hydroxybutyrate (GHB) (R = 0.360, p = 0.05). While epilepsy and psychiatric behaviors increase in severity with age, communication abilities and motor function tend to improve. iPSCs, which were differentiated into GABAergic neurons, represent the first in

[2] Evidence of redox imbalance in a patient with succinic semialdehyde dehydrogenase deficiency

  • Authors: A. Niemi, C. Brown, T. Moore, G. Enns, T. Cowan
  • Year: 2014
  • Venue: Molecular Genetics and Metabolism Reports
  • URL: https://www.semanticscholar.org/paper/e55849581ee59c657a0c26681c8c0bbceb4d0855
  • DOI: 10.1016/j.ymgmr.2014.02.005
  • PMID: 27896081
  • PMCID: 5121295
  • Citations: 10
  • Summary: A patient with SSADH deficiency is reported on, in whom low levels of blood reduced glutathione (GSH), and elevations of dicarboxylic acids in urine are found, suggestive of possible redox imbalance and/or mitochondrial dysfunction.
  • Evidence snippets:
  • Snippet 1 (score: 0.686) > Succinic semialdehyde dehydrogenase (SSADH; EC 1.2.1.24) deficiency is a rare disorder (OMIM 271980) of γ-aminobutyric acid (GABA) degradation caused by mutations in ALDH5A1 [1,2]. In this disorder, succinic semialdehyde, the transamination product of GABA, is not converted to succinic acid but instead into 4-hydroxybutyric acid (γ-hydroxybutyric acid, GHB) and other related metabolites including 4,5-dihydroxyhexanoic acids [3]. The diagnosis of SSADH deficiency is based on detecting elevated levels of 4-hydroxybutyric and related metabolites in body fluids including urine [3,4]. The clinical picture of SSADH deficiency is variable, with the most common manifestations being intellectual disability, expressive language deficits, epilepsy, hypotonia, ataxia, sleep disorders, and psychiatric disturbances [1,5,6]. Therapeutic interventions attempted in humans or murine models have included vigabatrin [7], phenobarbital [8], and taurine [9], but no treatment has shown consistent significant efficacy. Thus, novel therapeutic approaches are needed. > The pathophysiology of SSADH deficiency is not completely understood. It is unclear whether elevated GABA, GHB, or a secondary deficiency of tricarboxylic acid (TCA) cycle, or Krebs cycle, intermediates due to lack of conversion of succinic semialdehyde to succinic acid, or some another mechanism contributes to the clinical phenotype of these patients. Mitochondrial dysfunction and oxidative stress have been suggested to play a role by both in vitro and murine model studies [10][11][12][13][14][15][16]. Decreased total radical-trapping potential (TRAP), increased lipid peroxidation and altered antioxidant enzyme activities have been demonstrated in SSADH deficient mice [10,[13][14][15]17].

[3] An Unusual Presentation of Succinic Semialdehyde Dehydrogenase Deficiency: A Fatal Case of Severe Progressive Seizures in a Four-Month-Old Infant

  • Authors: Sara Idkaidak, Lila H. Abu-Hilal, Duha I Barghouthi, Osama M. Atawneh, Abdelrazzaq Abumayaleh et al.
  • Year: 2024
  • Venue: Cureus
  • URL: https://www.semanticscholar.org/paper/e676a85552293bb172d0a497ca410090c0827b4b
  • DOI: 10.7759/cureus.58326
  • PMID: 38752093
  • PMCID: 11095822
  • Citations: 1
  • Summary: A fetal case of a four-month-old female infant presenting with severe, progressive seizures leading to fatality is reported, highlighting the difficulties in controlling SSADH deficiency and the necessity for additional studies on successful therapy approaches.
  • Evidence snippets:
  • Snippet 1 (score: 0.684) > Succinic semialdehyde dehydrogenase (SSADH) deficiency is an uncommon genetic condition characterized by disrupting the normal processing of gamma-aminobutyric acid (GABA), a crucial inhibitory neurotransmitter in the brain. This condition follows an autosomal recessive pattern of inheritance [1]. The condition is caused by mutations in the ALDH5A1 gene, which is a member of the aldehyde dehydrogenase 5 family located on chromosome 6p22. Although the pathophysiology of this disease is not fully understood, part of the mechanism of the disease is related to the abnormal accumulation of the compound succinic semialdehyde caused by SSADH deficiency, which in turn is converted to gamma-hydroxybutyric acid (GHB) [2]. Also, the impairment of the function of the SSADH enzyme leads to a disruption of the metabolism of GABA. Both GABA and GHB contribute to pathophysiology. > The clinical features of SSADH deficiency are widely variable. SSADH deficiency can present at various ages, including late infancy and early childhood. The clinical presentation is marked by developmental delay and intellectual disability, along with notable delays in expressive language, low muscle tone, lack of coordination, movement abnormalities, and seizures [3,4]. Seizures can be seen in this disease and usually, the patient presents with generalized seizures and can be managed with appropriate medications. > Here we describe an unusual presentation of a four-month-old female patient diagnosed with SSADH deficiency who presented with severe progressive seizure leading to the death of the patient.

[4] Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective

  • Authors: T. Peters, U. Engelke, S. Boer, Joris T. G. Reintjes, J. Roullet et al.
  • Year: 2023
  • Venue: Journal of Inherited Metabolic Disease
  • URL: https://www.semanticscholar.org/paper/3bfb400717f8bd5fd000fd3838412c5628619685
  • DOI: 10.1002/jimd.12657
  • PMID: 37455357
  • Citations: 7
  • Summary: The intensities of selected features in plasma and urine of SSADHD patients positively correlated with the clinical severity score of epilepsy and psychiatric symptoms of those patients, and also showed a high mutual correlation.
  • Evidence snippets:
  • Snippet 1 (score: 0.683) > Succinic semialdehyde dehydrogenase deficiency (SSADHD; MIM #271980) is a rare neurometabolic disorder, with $450 patients described worldwide. 1It is caused by disruption of the gamma-aminobutyric acid (GABA) pathway (Figure 1).GABA-transaminase converts GABA into succinic semialdehyde (SSA), which is further metabolized by SSADH into succinic acid.In case of SSADHD, SSA is mainly converted into the alternative product gamma-(or 4-) hydroxybutyric acid (GHB).This metabolite can be found in urine, blood, and CSF of patients and is a hallmark of the disease, which is therefore also known as 4-hydroxybutyric aciduria. 2nother biomarker that is considered pathognomonic for SSADHD is 4,5-dihydroxyhexanoic acid (4,5-DHHA).It is thought to be formed from a reaction between SSA and pyruvate, catalyzed by pyruvate dehydrogenase, but this remains to be proven. 3he clinical symptoms of SSADHD are diverse, including motor and mental delay, hypotonia, speech delay, and epilepsy. 4This nonspecific clinical phenotype warrants biochemical and genetic confirmation when SSADHD is suspected.This is usually done by analysis of GHB in urine and by sequencing for variants of ALDH5A1, the gene encoding SSADH. 5The connection between the clinical symptoms and the metabolic disruptions is still largely unclear.An effective (curative) treatment is not yet available. 6Several new therapies based on the SSADHD disease mechanism are currently under development, mostly in the preclinical stage.Some clinical trials (phase I or II) have been performed, but without beneficial outcomes.For example, the only phase II clinical trial to date, which tested the GABA B receptor antagonist SGS-742, neither showed any improvement of cognition nor of cortical excitability. 7

[5] Clinical diagnosis and mutation analysis of four Chinese families with succinic semialdehyde dehydrogenase deficiency

  • Authors: Ping Wang, Fengying Cai, Lirong Cao, Yizheng Wang, Qianqian Zou et al.
  • Year: 2019
  • Venue: BMC Medical Genetics
  • URL: https://www.semanticscholar.org/paper/0398392b950970490f2b7e31054acd4dd93a252e
  • DOI: 10.1186/s12881-019-0821-z
  • PMID: 31117962
  • PMCID: 6532217
  • Citations: 12
  • Influential citations: 1
  • Summary: A novel mutation p.V267G located in the NAD binding domain, which is possibly crucial for this disease’s severity is described, which expands the mutation spectrum of ALDH5A1 and highlights the importance of molecular genetic evaluation in patients with SSADH deficiency.
  • Evidence snippets:
  • Snippet 1 (score: 0.660) > Succinic semialdehyde dehydrogenase (SSADH, OMIM: 271980) deficiency, also known as 4-hydroxybutyric aciduria, is a rare autosomal recessive genetic disorder that affects the degradation of γ-aminobutyric acid [1]. SSADH catalyzes succinic semialdehyde (SSA) to succinic acid (SA) in the final step of γ-aminobutyric acid (GABA) catabolism. In the absence of SSADH, SSA is converted into γ-hydroxybutyric acid (GHB) and other related metabolites. GHB can be converted to 3-deoxytetronic acid (3DT) or 2-deoxytetronic acid (2DT) via α or β oxidation. GABA and GHB accumulate in the brain, blood, urine, and cerebral spinal fluid. The clinical features of this disease are various and non-specific, including developmental delay, intellectual deficit, hypotonia, ataxia and seizures, and especially language delays [2][3][4]. Severity ranges from mild impairment to a relentlessly progressive neurodegenerative course with intractable seizures in infancy [5]. GABA A receptor down regulation was previously reported as one of the pathophysiological mechanisms [2], but current data reveal a surprisingly complex pattern of pathophysiology including oxidative stress parameters and dysregulation of autophagy and mitophagy [1]. > The gene of ALDH5A1 with a full length of 1605 bp containing 10 exons, located in chromosome 6p22.3, and codes 535 amino acids with the first 47 residues representing the mitochondrial targeting peptide [4,6]. The monomeric SSADH consisted of three domains: an oligomerization domain (174-195 and 525-535), a catalytic domain (308-508), and an N-terminal NAD-binding domain (residues 48-173, 196-307, and 509-524) that is responsible for the binding of NAD + to the enzyme [7].

[6] Succinic Semialdehyde Dehydrogenase Deficiency: An Update

  • Authors: M. Didiášová, A. Banning, H. Brennenstuhl, S. Jung-Klawitter, C. Cinquemani et al.
  • Year: 2020
  • Venue: Cells
  • URL: https://www.semanticscholar.org/paper/4e97fb0d65ee1803b2f0a03cfe1bf7dcefb3392a
  • DOI: 10.3390/cells9020477
  • PMID: 32093054
  • PMCID: 7072817
  • Citations: 42
  • Influential citations: 3
  • Summary: The main aim of this review is to discuss the potential of further therapy approaches that have so far not been tested in SSADH-D, such as pharmacological chaperones, read-through drugs, and gene therapy.
  • Evidence snippets:
  • Snippet 1 (score: 0.642) > Succinic semialdehyde dehydrogenase deficiency (SSADH-D, also called 4-hydroxybutyric aciduria, OMIM #271980) is an ultra-rare monogenic disorder of the γ-amino butyric acid (GABA) metabolism, with approximately 450 patients known to the literature (reviewed in [1,2]).The first case of SSADH-D was identified in 1981 in a patient excreting γ-hydroxybutyric acid (GHB) in the urine, and only two years later, the deficiency of succinic semialdehyde dehydrogenase (SSADH) activity was demonstrated to be the underlying cause [3,4].Variants of the ALDH5A1 gene have later been shown to be the cause of SSADH-D [5], which is inherited in an autosomal recessive fashion.Heterozygous carriers of one defective allele show no clinical signs of the disease, whereas the patients who are either homozygous or compound heterozygous for disease-causing variants are affected to a varying degree.Enzymatic dysfunction of SSADH leads to an accumulation of potentially neurotoxic metabolites, including GABA and GHB, as well as numerous other substances (see Table 1).Despite ambitious scientific effort, detailed knowledge about many aspects of the pathophysiology of the underlying enzyme defect is still lacking, and at present, no curative treatment that would directly target the enzyme deficiency is available for SSADH-D.As with many other rare disorders affecting the central nervous system (CNS), several symptomatic treatments have been and are currently investigated [6,7]. > Table 1.Accumulation of potentially harmful GABA metabolites in the body fluids of SSADH-D patients.Modified from [8].The clinical picture of SSADH-D is highly heterogeneous, and in many cases, the somewhat nonspecific nature of the symptoms may delay the diagnosis of patients without prior family history of the disease [1,9].
  • Snippet 2 (score: 0.631) > Succinic semialdehyde dehydrogenase deficiency (SSADH-D) is a genetic disorder that results from the aberrant metabolism of the neurotransmitter γ-amino butyric acid (GABA). The disease is caused by impaired activity of the mitochondrial enzyme succinic semialdehyde dehydrogenase. SSADH-D manifests as varying degrees of mental retardation, autism, ataxia, and epileptic seizures, but the clinical picture is highly heterogeneous. So far, there is no approved curative therapy for this disease. In this review, we briefly summarize the molecular genetics of SSADH-D, the past and ongoing clinical trials, and the emerging features of the molecular pathogenesis, including redox imbalance and mitochondrial dysfunction. The main aim of this review is to discuss the potential of further therapy approaches that have so far not been tested in SSADH-D, such as pharmacological chaperones, read-through drugs, and gene therapy. Special attention will also be paid to elucidating the role of patient advocacy organizations in facilitating research and in the communication between researchers and patients.
  • Snippet 3 (score: 0.495) > 1. Succinic Semialdehyde Dehydrogenase Deficiency: Clinical Phenotype, Genetics, and Standard Care

[7] Gene therapy for neurotransmitter‐related disorders

  • Authors: W. Chu, J. Ng, S. Waddington, M. Kurian
  • Year: 2024
  • Venue: Journal of Inherited Metabolic Disease
  • URL: https://www.semanticscholar.org/paper/c1b04457d92fbdfccfdbff1c35524f1e42a02e71
  • DOI: 10.1002/jimd.12697
  • PMID: 38221762
  • PMCID: 11108624
  • Citations: 9
  • Summary: Preclinical and clinical advances to address NT‐related diseases are presented, potential challenges that require careful considerations for NT gene therapy studies are summarized, and potential challenges that require careful considerations are summarised.
  • Evidence snippets:
  • Snippet 1 (score: 0.623) > Succinic semialdehyde dehydrogenase (SSADH) is a systemically expressed mitochondrial enzyme, with major expression in the brain and liver. 125In healthy individuals, synaptic GABA is transported into astrocytes by GAT, converted to succinic semialdehyde by GABA transaminase (GABA-T), then oxidised in tandem by SSADH to succinate, a substrate of the TCA cycle. 125In SSADHD (OMIM #271980), biallelic loss-of-function mutations in the encoding ALDH5A1 (6p22.3)gene result in the cytosolic conversion of succinic semialdehyde to γ-hydroxybutyrate (GHB), a neuromodulator with neurotoxic properties, instead. 126Excess accumulations of GABA, GHB and other GABA metabolites are found in brain and body fluids, but the exact pathophysiology remains to be elucidated. 125Clinical symptoms, including hypotonia, developmental delay, epilepsy, and behavioural and sleep disturbances, manifest in early childhood 126 ; age-dependent association in symptom severity and seizure types have been described. 127Post-mortem study of one patient also found amino acid, phospholipid, and NT disturbances. 128No effective treatment currently exists to address the underlying deficiency and downstream metabolic sequelae. > As the liver also expresses high levels of SSADH, and central and peripheral GHB rapidly equilibrates, 125 a liver-directed adenoviral approach was evaluated in a mouse SSADH-KO model. 129These mice recapitulate metabolic features observed in humans but have more severe phenotypes, with reduced survival up to P26 due to status epilepticus. 130

[8] A crucial active site network of titratable residues guides catalysis and NAD + binding in human succinic semialdehyde dehydrogenase

  • Authors: Samuele Cesaro, Marco Orlando, Ilaria Bettin, C. Longo, G. Spagnoli et al.
  • Year: 2024
  • Venue: Protein Science : A Publication of the Protein Society
  • URL: https://www.semanticscholar.org/paper/a288a30dabd43d3f42f175f6a4935e8c7bad91b6
  • DOI: 10.1002/pro.70024
  • PMID: 39731543
  • PMCID: 11681614
  • Summary: The identification of this weak bond network essential for cofactor binding and catalysis represents a first step to tackling the molecular basis for the molecular basis for this enzyme deficiency.
  • Evidence snippets:
  • Snippet 1 (score: 0.605) > Human succinic semialdehyde dehydrogenase is a mitochondrial enzyme fundamental in the neurotransmitter γ‐aminobutyric acid catabolism. It catalyzes the NAD+‐dependent oxidative degradation of its derivative, succinic semialdehyde, to succinic acid. Mutations in its gene lead to an inherited neurometabolic rare disease, succinic semialdehyde dehydrogenase deficiency, characterized by mental and developmental delay. Due to the poor characterization of this enzyme, we carried out evolutionary and kinetic investigations to contribute to its functional behavior, a prerequisite to interpreting pathogenic variants. An in silico analysis shows that succinic semialdehyde dehydrogenases belong to two families, one human‐like and the other of bacterial origin, differing in the oligomeric state and in a network of active site residues. This information is coupled to the biophysical–biochemical characterization of the human recombinant enzyme uncovering that (i) catalysis proceeds by an ordered bi–bi mechanism with NAD+ binding before the aldehyde that exerts a partial non‐competitive inhibition; (ii) a stabilizing complex between the catalytic Cys340 and NAD+ is observed and interpreted as a protective mechanism; and (iii) a concerted non‐covalent network assists the action of the catalytic residues Cys340 and Glu306. Through mutational analyses of Lys214, Glu306, Cys340, and Glu515 associated with pH studies, we showed that NAD+ binding is controlled by the dyad Lys214‐Glu515. Moreover, catalysis is assured by proton transfer exerted by the same dyad networked with the catalytic Glu306, involved in catalytic Cys340 deprotonation/reprotonation. The identification of this weak bond network essential for cofactor binding and catalysis represents a first step to tackling the molecular basis for its deficiency.

[9] The continuously evolving phenotype of succinic semialdehyde dehydrogenase deficiency

  • Authors: N. Juliá-Palacios, Oya Kuseyri Hübschmann, M. Olivella, Roser Pons, Gabriella Horvath et al.
  • Year: 2024
  • Venue: Journal of Inherited Metabolic Disease
  • URL: https://www.semanticscholar.org/paper/4e19bbf0e8cbdeb4eee833162c7038072d77b2ba
  • DOI: 10.1002/jimd.12723
  • PMID: 38499966
  • Citations: 9
  • Summary: The diversifying characteristics of disease phenotype during the disease course, highlighting movement disorders, widens the knowledge on the genotypic spectrum of SSADHD and emphasizes a reliable application of in silico approaches.
  • Evidence snippets:
  • Snippet 1 (score: 0.604) > Succinic semialdehyde dehydrogenase deficiency (SSADHD; OMIM #271980) is the most frequent inherited disorder of γ-aminobutyric acid (GABA) metabolism and is caused by homozygous or compound heterozygous variants in the ALDH5A1 gene (610045) on chromosome 6p22.Its impairment leads to the accumulation of large quantities of GABA and γ-hydroxybutyric acid (GHB; 4-hydroxybutyric), especially in the central nervous system (CNS). > GABA, the CNS major inhibitory neurotransmitter, is formed from glutamate by pyridoxal-5-phosphatedependent glutamate decarboxylase.It is catabolized into succinic acid through the sequential action of two mitochondrial enzymes, GABA transaminase (GABA-T) and succinic semialdehyde dehydrogenase (SSADH).Succinic acid enters the Krebs cycle and is converted to 2-oxoglutarate, which further leads to the synthesis of glutamate.In the absence of SSADH, the accumulation of succinic semialdehyde results in its conversion to GHB. > High concentrations of GABA and GHB, are detectable in cerebrospinal fluid (CSF) and urine of individuals with SSADHD and are related to the neurological manifestation of the disease, but this is not a known pathophysiological explanation as far as the literature states, and there still is need of further study.In addition, recent evidence suggests that multiple metabolic perturbations may be associated with the pathophysiology including involvement of the mitogen-activated protein kinases (MAPK) pathway affecting the myelination, 1 dysregulation of autophagy and oxidative stress via mTOR pathway 2 and astrogliosis and myelin-related phospholipid reduction. 3n SSADHD, the first symptoms appear at an average age of 11 months (range 0-44 months).However, the mean age at diagnosis was reported as 6.6 years. 4,5

[10] Functional Characterization of a Spectrum of Genetic Variants in a Family with Succinic Semialdehyde Dehydrogenase Deficiency

  • Authors: M. Didiášová, Samuele Cesaro, S. Feldhoff, Ilaria Bettin, Nana Tiegel et al.
  • Year: 2024
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/867a88fcf42cd64945d27484cdac30b45471df5b
  • DOI: 10.3390/ijms25105237
  • PMID: 38791277
  • PMCID: 11121183
  • Citations: 2
  • Summary: A treatment with substances that support protein folding by either increasing chaperone protein expression or by chemical means did not increase the expression of the pathogenic variants of the SSADH deficiency patient, however, stabilization of the folding of pathogenic SSADH variants by other substances may provide a treatment option for this disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.598) > The catabolic pathway of the neurotransmitter γ-amino butyric acid (GABA) leads to the production of succinic semialdehyde (SSA), which is normally converted into succinate by a mitochondrial enzyme, succinic semialdehyde dehydrogenase (SSADH, reviewed in [1,2]).In the absence of SSADH activity, SSA and GABA accumulate in the cells and in the extracellular fluids [3,4].In addition, a large fraction of SSA is converted into a toxic metabolite, γ-hydroxy butyric acid (GHB; reviewed in [1,2]). > Impairment of SSADH activity is caused by mutations in the ALDH5A1 gene, which resides on chromosome 6p22 and encodes the SSADH enzyme, the deficiency of which results in a rare genetic disease, SSADH deficiency (SSADH-D) [5,6].The disease prevalence has been estimated to be about 1 in 460,000 [7].The patients usually suffer from a varying degree of mental retardation, behavioral problems with autistic features, muscle hypotonia, and lack of speech.Some SSADH-D patients also have epileptic seizures that can be very severe and may result in sudden unexpected death from epilepsy [8][9][10][11][12].Accumulation of the GABA metabolites is observed in the tissues and body fluids of the patients and can be used as a diagnostic tool.Recent years have brought about several interesting hypotheses on the molecular mechanisms of SSADH-D, with novel ideas for treatment options.The current understanding of SSADH-D and the molecular mechanism of this disease have recently been discussed in review articles that the readers should consider for more detailed information on this disease [2,[12][13][14]. > SSADH-D is a recessively inherited disease in which a large spectrum of pathogenic ALDH5A1 gene variants have been described, and the sequencing of the ALDH5A1 gene is usually performed to verify the diagnosis [1,[15][16][17].

[11] Novel biomarkers and age-related metabolite correlations in plasma and dried blood spots from patients with succinic semialdehyde dehydrogenase deficiency

  • Authors: Trevor O. Kirby, Dana C. Walters, Xutong Shi, Coleman T. Turgeon, P. Rinaldo et al.
  • Year: 2020
  • Venue: Orphanet Journal of Rare Diseases
  • URL: https://www.semanticscholar.org/paper/6ea99377dfb49d27d455c61a8c49653296c7a14c
  • DOI: 10.1186/s13023-020-01522-5
  • PMID: 32967698
  • PMCID: 7510106
  • Citations: 5
  • Summary: Age-dependent acylcarnitine correlations may represent metabolic compensation responsive to age-related changes in GHB and GABA and are highlighted in a study highlights novel biomarkers in SSADHD and expands the metabolic pathophysiology of this rare disorder of GABA metabolism.
  • Evidence snippets:
  • Snippet 1 (score: 0.579) > Succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD) is a rare disorder on the GABA metabolic pathway. The product of glutamate decarboxylation, GABA is catabolized to succinic acid in a two-enzyme sequence, including generation of succinic semialdehyde (SSA) catalyzed by GABA-aminotransferase and the further oxidation of SSA to succinic acid catalyzed by SSADH [10]. The backbone of GABA thus enters the tricarboxylic acid cycle for further metabolism. SSADHD is frequently referred to as γ-hydroxybutyric aciduria. This is due to the fact that accumulated SSA, in the absence of functional SSADH activity, is converted to γ-hydroxybutyrate (GHB), the latter being a compound with diverse and still poorly understood neuromodulatory roles [13]. In addition to increased GABA and GHB, patients manifest a broad variety of additional metabolic abnormalities, which have recently been summarized [2,11]. > The phenotype of SSADHD encompasses developmental and speech delays, hypotonia, neuropsychiatric morbidity (attention deficit disorder, obsessive compulsive behavior), and seizures in ~50% of patients. The metabolic signature includes elevated GHB and GABA in physiological fluids, among other metabolites [11]. The incidence of SSADHD is estimated to be 1:10 6 , but expanding molecular genetic studies are likely to reveal a higher prevalence. To explore the clinical and metabolic evolution of SSADHD, we have recently embarked on an NIHfunded natural history study. Enrolling up to 55 patients (any age), this study encompasses multiple neuroimaging and electrophysiological evaluations over a 5-year period. An important ancillary component of clinical evaluation is the collection of biospecimens yearly, including plasma, white and red cells, DNA and RNA, hair, saliva, stool, urine, fibroblasts, and others.

[12] Understanding the Molecular Mechanisms of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD): Towards the Development of SSADH-Targeted Medicine

  • Authors: H. Lee, Gabrielle E. McGinty, P. Pearl, A. Rotenberg
  • Year: 2022
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/bfe2b6f01467505a287f076fdc85969443625568
  • DOI: 10.3390/ijms23052606
  • PMID: 35269750
  • PMCID: 8910003
  • Citations: 23
  • Influential citations: 1
  • Summary: A description of a novel SSADHD mouse model that enables ‘on-demand’ SSADH restoration, allowing proof-of-concept studies to fine-tune SSadH restoration in preparation for eventual human trials.
  • Evidence snippets:
  • Snippet 1 (score: 0.571) > Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare genetic disorder caused by inefficient metabolic breakdown of the major inhibitory neurotransmitter, γ-aminobutyric acid (GABA). Pathologic brain accumulation of GABA and γ-hydroxybutyrate (GHB), a neuroactive by-product of GABA catabolism, leads to a multitude of molecular abnormalities beginning in early life, culminating in multifaceted clinical presentations including delayed psychomotor development, intellectual disability, hypotonia, and ataxia. Paradoxically, over half of patients with SSADHD also develop epilepsy and face a significant risk of sudden unexpected death in epilepsy (SUDEP). Here, we review some of the relevant molecular mechanisms through which impaired synaptic inhibition, astrocytic malfunctions and myelin defects might contribute to the complex SSADHD phenotype. We also discuss the gaps in knowledge that need to be addressed for the implementation of successful gene and enzyme replacement SSADHD therapies. We conclude with a description of a novel SSADHD mouse model that enables ‘on-demand’ SSADH restoration, allowing proof-of-concept studies to fine-tune SSADH restoration in preparation for eventual human trials.
  • Snippet 2 (score: 0.558) > Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare genetic metabolic disorder caused by loss-of-function mutations of the ALDH5A1 gene. ALDH5A1 encodes SSADH which is essential for the mitochondrial breakdown of succinic semialdehyde (SSA), a γ-aminobutyric acid (GABA) downstream metabolite, into succinate. In the absence of SSADH, SSA conversion to succinate is prohibited, leading to SSA conversion to γ-hydroxybutyrate (GHB). Both GABA and GHB are accumulated in the brain and body fluids (cerebrospinal fluid, blood) up to pathologic levels, resulting in numerous downstream neurological and metabolic abnormalities. > To date, SSADHD treatments remain symptomatic and only minimally effective. A fundamentally different approach is targeted SSADH restoration, which may be accomplished via gene therapy or enzyme replacement therapy (ERT). While gene and enzyme replacement therapies are still in their infancy, we envision that the current technology and research environment enable a quick transition from basic bench side research to clinical trials (Figure 1A). We therefore describe our ongoing work aimed to develop SSADH-targeted treatments. By generating a novel SSADHD mouse model which allows 'on-demand' SSADH restoration, we aim to understand the impact of SSADH restoration from molecular level to animal behaviors. The ongoing SSADHD Natural History Study provides correlating clinical data for relevant biomarkers development. These combined efforts will accelerate the transition from bench to bedside development of the eventual safe and effective therapeutic products. > Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW 2 of 15 and research environment enable a quick transition from basic bench side research to clinical trials (Figure 1A). We therefore describe our ongoing work aimed to develop SSADHtargeted treatments. By generating a novel SSADHD mouse model which allows 'on-demand' SSADH restoration, we aim to understand the impact of SSADH restoration from molecular level to animal behaviors. The ongoing SSADHD Natural History Study provides correlating clinical data for relevant biomarkers development.

[13] Succinic Semialdehyde Dehydrogenase Deficiency: In Vitro and In Silico Characterization of a Novel Pathogenic Missense Variant and Analysis of the Mutational Spectrum of ALDH5A1

  • Authors: H. Brennenstuhl, M. Didiášová, B. Assmann, M. Bertoldi, G. Molla et al.
  • Year: 2020
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/b03a6095722d5f7729750941e91b4c7377932074
  • DOI: 10.3390/ijms21228578
  • PMID: 33203024
  • PMCID: 7696157
  • Citations: 7
  • Summary: A patient is presented with a severe phenotype of SSADHD caused by a novel genetic variant c.728T > C that leads to an exchange of leucine to proline at residue 243, located within the highly conserved nicotinamide adenine dinucleotide (NAD)+ binding domain ofSSADH.
  • Evidence snippets:
  • Snippet 1 (score: 0.562) > Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare, monogenic disorder affecting the degradation of the main inhibitory neurotransmitter γ-amino butyric acid (GABA). Pathogenic variants in the ALDH5A1 gene that cause an enzymatic dysfunction of succinic semialdehyde dehydrogenase (SSADH) lead to an accumulation of potentially toxic metabolites, including γ-hydroxybutyrate (GHB). Here, we present a patient with a severe phenotype of SSADHD caused by a novel genetic variant c.728T > C that leads to an exchange of leucine to proline at residue 243, located within the highly conserved nicotinamide adenine dinucleotide (NAD)+ binding domain of SSADH. Proline harbors a pyrrolidine within its side chain known for its conformational rigidity and disruption of protein secondary structures. We investigate the effect of this novel variant in vivo, in vitro, and in silico. We furthermore examine the mutational spectrum of all previously described disease-causing variants and computationally assess all biologically possible missense variants of ALDH5A1 to identify mutational hotspots.

[14] Sensorineural Hearing Loss in a Child with Succinic Semialdehyde Dehydrogenase Deficiency

  • Authors: M. Parezanović, N. Ilić, S. Ostojic, G. Stevanović, J. Jecmenica et al.
  • Year: 2023
  • Venue: Balkan Journal of Medical Genetics : BJMG
  • URL: https://www.semanticscholar.org/paper/d7a837ce93c4cc347de8bfe1971982fb6d37354e
  • DOI: 10.2478/bjmg-2023-0008
  • PMID: 37576789
  • PMCID: 10413887
  • Citations: 2
  • Summary: A five-year-old male patient, homozygous for the pathogenic variant (NM_170740:c.1265G>A) in ALDH5A1 presenting with an unexpected association of typical SSADH deficiency manifestations with bilateral sensorineural hearing loss (SNHL) is reported, hoping that this case will contribute to the understanding of phenotypic complexity of SSadH deficiency.
  • Evidence snippets:
  • Snippet 1 (score: 0.529) > The first description of succinic semialdehyde dehydrogenase deficiency is found in Jakobs et al. from 1981, followed by the elucidation of its genetic basis and aggregation of significant amount of data reflecting its clinical spectrum. 1,4,12 Numerous pathogenic variants in ALDH5A1 associated with SSADH deficiency have been reported, but precise genotype-phenotype correlation was not yet established. 2,13 Additionally, the relationship between the genetic change and residual succinic semialdehyde dehydrogenase activities lacked consistency. 2 ue to its heterogeneous and often non-specific clinical presentation, SSADH deficiency may be significantly underdiagnosed. 5][16] In the case of our patient, hypotonia was noticeable in early infancy. The course of the disease remained non-progressive, despite the notion that some SSADH deficiency patients with early onset have severe complications including extrapyramidal signs, seizures, regression and even death in infancy. In the case of our patient, hypotonia and global developmental delay are the hallmarks of the disease from the beginning. Up to the age of five years, our patient has remained seizure free. > Quality of life for SSADH deficiency patients could be significantly reduced in cases of pronounced neuropsychiatric problems, among which a lack of attention and aggressive behavior begin in early childhood while disabling obsessive-compulsive disorder occur mostly in adolescence and adulthood. 7-9 Similar manifestations have not been encountered yet in the boy we present, apart from a single visit to the pediatric emergency department at the age of four years due to unexplained agitation lasting for several hours. Given moderate sleeping difficulties, our patient is using melatonin with good results. A clinical severity scoring (CSS) system was recently proposed for evaluating SSADH patients, based on cognitive aspects, communication skills, motor function, epilepsy, and psychiatric aspect of the disease. 17 The CSS ranges from 5-25 (average (17.3), with higher scores correlating with milder presentation. Our patient's score of 17 at 5 years of age is almost the exact average of the SSADH patients group involved in study that established the CSS.

[15] Metabolic Stroke: A Novel Presentation in a Child with Succinic Semialdehyde Dehydrogenase Deficiency

  • Authors: S. Yoganathan, Gautham Arunachal, L. Kratz, Mugil Varman, Maya Thomas et al.
  • Year: 2020
  • Venue: Annals of Indian Academy of Neurology
  • URL: https://www.semanticscholar.org/paper/1194fabd46eb74779bfa11c723054ac12306e5b1
  • DOI: 10.4103/aian.AIAN_213_18
  • PMID: 32055132
  • PMCID: 7001443
  • Citations: 8
  • Influential citations: 1
  • Summary: A 15-month-old girl with SSADH deficiency presenting with developmental delay, language deficits, and acute-onset right hemiparesis, following recovery from a diarrheal illness is described.
  • Evidence snippets:
  • Snippet 1 (score: 0.510) > SSADH deficiency is a rare under-recognized disorder of GABA metabolism, although the exact incidence is not known. In our case, developmental delay, language deficit, hypotonia, hyporeflexia, and autistic traits were identified as described in the literature. To the best of our knowledge, this is the first report of a child with SSADH deficiency presenting as stroke mimic. The biochemical defect in SSADH deficiency is a failure to oxidize succinic semialdehyde to succinic acid. GABA transamination to succinic semialdehyde in the metabolic pathway is followed by its conversion to succinic acid which enters the Krebs cycle. [2] However, in the absence of SSADH, succinic semialdehyde is reduced to 4-hydroxybutyric acid which is a neurotoxic agent. [2] Predominant right-sided weakness in our case could be explained by the asymmetric involvement of the basal ganglia. > Metabolic stroke has been reported in patients with homocystinuria, methylmalonic aciduria, glutaric aciduria Type I and II, isovaleric aciduria, propionic aciduria, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), Fabry disease, and urea cycle disorders. [3,4] The exact pathophysiology of stroke in patients with SSADH is unclear. It is possible that 4-hydroxybutyric acid, a toxic metabolite that accumulates endogenously in children with SSADH deficiency, is neurotoxic as seen in our patient, leading onto the clinical manifestations. Although the exact reason behind such a presentation is unclear, we can derive at an indirect explanation through the murine models of SSADH. It is postulated that hyperGABAergic state and elevated 4-hydroxybutyric acid affect neurotransmission and also cause escalation of various parameters of oxidative stress. [5] The catabolic process induced by infection as seen in our case might have worsened the underlying oxidative stress, followed by recovery with the cessation of the catabolic process.

[16] Succinic semialdehyde dehydrogenase deficiency: a metabolic and genomic approach to diagnosis

  • Authors: Kevin E. Glinton, C. Gijavanekar, Abbhirami Rajagopal, Laura Mackay, Kirt A. Martin et al.
  • Year: 2024
  • Venue: Frontiers in Genetics
  • URL: https://www.semanticscholar.org/paper/4f1b260e19af51f9fd804fc64959c9f7f1d6749c
  • DOI: 10.3389/fgene.2024.1405468
  • PMID: 39011401
  • PMCID: 11247174
  • Citations: 5
  • Summary: This study utilized an integrated approach to diagnosis of SSADHD by examining molecular, clinical, and metabolomic data from a single large commercial laboratory and showed that patients with this disorder have a clear metabolomic signature that, along with molecular and clinical findings, may allow for more rapid and efficient diagnosis.
  • Evidence snippets:
  • Snippet 1 (score: 0.503) > Genomic sequencing offers an untargeted, data-driven approach to genetic diagnosis; however, variants of uncertain significance often hinder the diagnostic process. The discovery of rare genomic variants without previously known functional evidence of pathogenicity often results in variants being overlooked as potentially causative, particularly in individuals with undifferentiated phenotypes. Consequently, many neurometabolic conditions, including those in the GABA (gamma-aminobutyric acid) catabolism pathway, are underdiagnosed. Succinic semialdehyde dehydrogenase deficiency (SSADHD, OMIM #271980) is a neurometabolic disorder in the GABA catabolism pathway. The disorder is due to bi-allelic pathogenic variants in ALDH5A1 and is usually characterized by moderate-to-severe developmental delays, hypotonia, intellectual disability, ataxia, seizures, hyperkinetic behavior, aggression, psychiatric disorders, and sleep disturbances. In this study, we utilized an integrated approach to diagnosis of SSADHD by examining molecular, clinical, and metabolomic data from a single large commercial laboratory. Our analysis led to the identification of 16 patients with likely SSADHD along with three novel variants. We also showed that patients with this disorder have a clear metabolomic signature that, along with molecular and clinical findings, may allow for more rapid and efficient diagnosis. We further surveyed all available pathogenic/likely pathogenic variants and used this information to estimate the global prevalence of this disease. Taken together, our comprehensive analysis allows for a global approach to the diagnosis of SSADHD and provides a pathway to improved diagnosis and potential incorporation into newborn screening programs. Furthermore, early diagnosis facilitates referral to genetic counseling, family support, and access to targeted treatments–taken together, these provide the best outcomes for individuals living with either GABA-TD or SSADHD, as well as other rare conditions.

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.